US Pat. No. 10,918,644

CHEMOTHERAPEUTIC DRUG COMPOSITION

YEDITEPE UNIVERSITESI, I...

1. A drug composition for treatment of kidney cancer, comprising a solution of ABT-737, and a final solution concentration of 75 mg/kg; andthe drug composition further comprises an Everolimus solution, and a final concentration of the Everolimus solution is 2 mg/kg;
wherein the kidney cancer is rapalog-resistant advanced kidney cancer.
US Pat. No. 10,919,668

POLYESTER LABEL AND PACKAGING CONTAINER

TOYOBO CO., LTD., Osaka ...

1. A polyester label comprising a drawn base film having a thickness of 8 ?m or more and 30 ?m or less before heat shrinkage, wherein the polyester label after aging 60 days at 45° C. satisfies the following requirements (1) to (6):(1) the base film after heat shrinkage has an intrinsic viscosity of 0.58 dl/g or more,
(2) the label has a tensile elongation at break of 5% or more in both a main shrinkage direction of the label and a direction orthogonal to the main shrinkage direction of the label, wherein the main shrinkage direction is the direction with the largest shrinkage of the film,
(3) when an absorbancy at 1340 cm?1 and an absorbancy at 1410 cm?1 are measured for the base film constituting the label by a polarized ATR method, a difference between an absorbancy ratio (absorbancy at 1340 cm?1/absorbancy at 1410 cm?1) in the main shrinkage direction of the label and an absorbancy ratio (absorbancy at 1340 cm?1/absorbancy at 1410 cm?1) in the direction orthogonal to the main shrinkage direction of the label is 0.2 or more,
(4) when a reversible heat capacity curve is measured for the label after shrinkage with a temperature modulated differential scanning calorimeter, the base film constituting the label has a difference in specific heat capacity ?Cp, as defined by the following formula, of 0.2 J/(g·° C.) or more:
?Cp (J/(g·° C.))=(heat capacity at a temperature higher than Tg)?(heat capacity at a temperature lower than Tg),
(5) the label has a difference between a maximum value and a minimum value of a length in a vertical direction of the label of 3 mm or less with respect to the strains of the label, and
(6) the label has a tensile strength at break in the direction orthogonal to the main shrinkage direction of the label of 5 MPa or more and 60 MPa or less.
US Pat. No. 10,919,925

LIQUID COMPOSITION FOR RECONSTITUTING PRESSED POWDER COSMETICS

1. A composition for reconstituting loosened compact cosmetic powders, comprising:84.44 wt. % Hamamelis virginiana;
13.7 wt. isopropyl alcohol;
1.57 wt. % decyl glucoside;
0.10 wt. % lavender essential oil;
0.05 wt. % jojoba oil;
0.05 wt. % fractionated coconut oil; and
0.05 wt. % vitamin E.
US Pat. No. 10,920,181

AEROSOL CLEANING COMPOSITION

Illinois Tool Works Inc.,...

1. A nonflammable aerosol cleaning composition, comprising:trans 1,2-dichloroethylene at concentration of about 50% to about 75% by weight of the cleaning composition;
1,1,1,2,2,3,4,5,5,5-decafluoropentane at concentration of about 5% to about 25% by weight of the cleaning composition;
1,1,1,3,3-pentafluoropropane at concentration of about 3% to about 20% by weight of the cleaning composition; and
a blend of propellants including 1,1,1,2-tetrafluoroethane (HFC-134a) and carbon dioxide.
US Pat. No. 10,920,182

AFFINITY-BASED ANALYTICAL PURIFICATION OF BIOTHERAPEUTICS FOR BIOPROCESS MONITORING

GENZYME CORPORATION, Cam...

1. A method of developing a multi-step bioprocess for producing a non-antibody protein (NAP), the method comprising:a) processing a NAP comprising an engineered protein or enzyme using a particular bioprocess unit operation within the multi-step bioprocess;
b) purifying the NAP from solution within the multi-step bioprocess by:
i) contacting a heterogeneous solution comprising the NAP with an affinity construct comprising a solid support coupled to an affinity ligand that binds the NAP,
ii) isolating the affinity-purified NAP from the heterogeneous solution, and
iii) determining a critical quality attribute (CQA) of the affinity-purified NAP,
wherein the CQA is a physical, chemical, biological, or microbiological property or characteristic of the NAP selected from the group consisting of product purity, potency, charged isoform profile, post-translational modifications, oxidation, reductions, deamidation, adduct formation, clipped forms, enzymatic cleavage, specific activity, peptide map, dimer content, product aggregation, site specific glycosylation, total glycans, and glycosylation profile;
c) providing a transformed CQA of the affinity-purified NAP by calculating a ratio of the determined CQA of the affinity-purified NAP to a determined CQA of the NAP purified by a multi-step process train purification; and
d) developing the multi-step bioprocess by modifying the particular bioprocess unit operation based on the transformed CQA.
US Pat. No. 10,918,646

METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS

Constellation Pharmaceuti...

1. A method of treating myelofibrosis in a subject comprising administering to the subject a therapeutically effective amount of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,920,184

MEMBRANE FOR RECONSTRUCTED TISSUE COMPRISING PORES OF SEVERAL DIAMETERS

1. A monolayer membrane for cell culture comprising at least two types of pores:(i) pores having an average diameter between 0.1 and 1 ?m, at a density of 1×105 to 1×108 pores per cm2 of membrane, and
(ii) pores having an average diameter between 2 and 12 ?m, at a density of 0.5×102 to 5×103 pores per cm2 of membrane,
with the two types of pores crossing through the thickness of the membrane from one side to the other.
US Pat. No. 10,918,649

SYSTEM FOR PROVIDING BIRTH CONTROL

The Population Council, I...

1. A reusable vaginal system for preventing pregnancy comprising: a silicone elastomer ring body having a platinum concentration of approximately 3 ppm to approximately 10 ppm and a hydride/vinyl ratio from approximately 1:1 to approximately 1.3:1 before curing, wherein the silicone elastomer ring body comprises two cores, each core comprising a condensation-cure silicone elastomer and dibutyltin dilaurate; the cores containing, in total, approximately 103 mg of segesterone acetate, and approximately 17.4 mg of ethinyl estradiol;wherein the system is configured to release an approximate average of 0.15 mg/day of segesterone acetate and an approximate average of 0.013 mg/day of ethinyl estradiol, or bioequivalent amounts thereof, for up to 13 cycles of 21 days each; and
wherein approximately 80% to approximately 90% of the ethinyl estradiol is recoverable from the system after approximately 18 months of storage at 25° C. and 60% relative humidity and wherein no more than approximately 10% to approximately 20% of the ethinyl estradiol undergoes hydrosilylation with unreacted hydrosilane in the ring body after approximately 18 months of storage at 25° C. and 60% relative humidity.
US Pat. No. 10,918,650

METHOD OF TREATING MELANOMA USING AN INHIBITOR OF AN ATYPICAL PROTEIN KINASE C

UNIVERSITY OF SOUTH FLORI...

1. A method of treating a melanoma in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of an atypical protein kinase C (aPKC),wherein the aPKC inhibitor is [4-(5-amino-4-carbamoylimidazol-1-yl)-2,3-dihydroxycyclopentyl]methyl dihydrogen phosphate (ICA-1).
US Pat. No. 10,919,931

IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS

IMMATICS BIOTECHNOLOGIES ...

1. A peptide consisting of the amino acid sequence of GLWHHQTEV (SEQ ID NO: 21) in the form of pharmaceutically acceptable salt, wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.
US Pat. No. 10,920,187

ULTRAVIOLET RADIATION PRE-TREATMENT OF WASTEWATER, IMPROVING ITS UTILITY FOR ALGAL CULTIVATION

Boise State University, ...

1. A method of increasing algae production in an agricultural wastewater treatment medium comprising:(a) measuring the light absorbance level of agricultural wastewater from at least one wavelength between about 300 nm to about 430 nm prior to treating the agricultural wastewater;
(b) setting a short wavelength UVc radiation dosage based on the absorbance level;
(c) treating the agricultural wastewater with short wavelength UVc radiation at a UVc dose of 189.3 mW-s/cm2 to about 757.1 mW-s/cm2 for less than about 300 seconds prior to introduction of algae, thereby generating pre-treated wastewater;
(d) adding the algae to the pre-treated wastewater and allowing the algae to grow and absorb nutrients present in the pre-treated wastewater, wherein algae growth and production is increased in the pre-treated wastewater in an appropriate absorbance range by as much as 88% over wastewater that is not pretreated by the short wavelength UVc radiation; and
(e) harvesting the algae or algae bio-material, and recycling the pre-treated wastewater; wherein the agricultural wastewater has at least about 105 CFU microbes per ml of the wastewater before the treating with the short wavelength UVc radiation.
US Pat. No. 10,918,651

METHOD FOR LOWERING THYROTROPIN LEVELS IN ADULTS

University of Louisiana a...

1. A method for reducing thyroid stimulating hormone levels in adults by administering Alpha Glycerylphosphoryl Choline to said adult.
US Pat. No. 10,919,932

BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF

The Regents of the Univer...

1. A conjugate comprising:(a) a peptide that binds to an integrin, wherein the peptide comprises the amino acid sequence RGDLX1X2X3 (SEQ ID NO:4), wherein X1 and X2 are independently selected amino acids and X3 is L or I;
(b) a first polyethylene glycol (PEG) moiety covalently attached to the amino-terminus of the peptide; and
(c) a second PEG moiety covalently attached to the carboxyl-terminus of the peptide,
wherein the conjugate further comprises an imaging agent or a therapeutic agent covalently attached to the peptide, the first PEG moiety, or the second PEG moiety,
wherein the imaging agent is selected from the group consisting of a radionuclide, biotin, a fluorophore, a fluorescent protein, an antibody, horseradish peroxidase, alkaline phosphatase, and combinations thereof, and
wherein the therapeutic agent is selected from the group consisting of a radionuclide, a pro-apoptotic peptide, a nanoparticle, a chemotherapeutic agent, a nanodroplet, a liposomal drug, a cytokine, and combinations thereof.
US Pat. No. 10,920,188

CULTURE MEDIUM FOR THE ISOLATION OF CLINICAL SAMPLES OF SPECIES SUCH AS MYCOPLASMA INCLUDING THOSE WHICH ARE NOT CULTURABLE IN TRADITIONAL MEDIA

C.P.M. DI CLAUDIO PIERMAT...

1. A method for in vitro cultivating, isolating, and/or identifying Mycoplasma and/or Ureaplasma genus microorganisms comprisingculturing the microorganisms of Mycoplasma and/or Ureaplasma genus in a culture medium comprising:
hydrolysate of bovine blood;
extract from beef heart;
enzymatic hydrolysate of bovine heart;
enzymatic hydrolysate of milk proteins;
enzymatic hydrolysate of soybeans proteins;
enzymatic hydrolysate of animal tissue;
autolysate or hydrolysate from Sacharomyces cerevisiae;
salts of trivalent metals;
aromatic amino acids;
a mixture of globular protein and plasma; and
fibrous proteins, and
isolating the microorganisms of Mycoplasma and/or Ureaplasma genus by evaluating a color change in the medium;
wherein
red or turbid red indicates Mycoplasma hominis;
red indicates Ureaplasma urealyticum or Ureaplasma parvum;
turbid yellow indicates Mycoplasma pneumonia or Mycoplasma hyorhinis;
orange or yellow indicates Mycoplasma genitalium;
brilliant yellow or turbid yellow indicates Mycoplasma fermentans or Mycoplasma penetrans; and
yellow or turbid yellow indicates Mycoplasma pirum.
US Pat. No. 10,918,652

COMPOSITIONS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES AND DISORDERS

Claridei Laboratories, In...

1. A method of treating a dermatological disease or disorder at least partially characterized by an abnormally high skin pH, comprising administering a therapeutically effective amount of a topical dermatological formulation with a pH between 4.2 and 4.8 to the affected skin of a patient,wherein the dermatological formulation comprises:vinegar powder,
glucono delta-lactone,
an EDTA calcium chelation agent,
a preservative, and
a gelling agent; andwherein the disease or disorder is selected from:a) atopic dermatitis;
b) intertrigo;
c) webspace infections;
d) pitted keratolysis;
e) foul-smelling feet and axillae;
f) erythrasma;
g) ichthyosis;
h) psoriasis;
i) acne;
j) rosacea;
k) seborrhoeic dermatitis;
l) diaper dermatitis;
m) irritant contact dermatitis;
n) keratosis pilaris; and
o) xerosis.
US Pat. No. 10,919,933

CELL EPITOPES AND COMBINATION OF CELL EPITOPES FOR USE IN THE IMMUNOTHERAPY OF MYELOMA AND OTHER CANCERS

IMMATICS BIOTECHNOLOGIES ...

1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a composition comprising a population of activated T cells that selectively recognize cancer cells that present a peptide consisting of the amino acid sequence SEQ ID NO: 29,wherein the activated T cells are produced by contacting T cells with the peptide loaded onto a human MHC molecule expressed on the surface of an antigen-presenting cell for a period of time sufficient to activate the T cells,
wherein SEQ ID NO: 29 binds to a class I MHC molecule,
wherein said cancer is selected from myeloma, lung cancer, kidney cancer, brain cancer, stomach cancer, colon or rectal cancer, liver cancer, prostate cancer, leukemia, breast cancer, Merkel cell carcinoma (MCC), melanoma, ovarian cancer, esophageal cancer, urinary bladder cancer, endometrial cancer, gall bladder cancer, pancreatic cancer, and bile duct cancer.
US Pat. No. 10,920,189

GENOME-WIDE RATIONALLY-DESIGNED MUTATIONS LEADING TO ENHANCED LYSINE PRODUCTION IN E. COLI

Inscripta, Inc., Boulder...

1. An engineered E. coil cell comprising the following variant sequences: a dapA protein having the amino add sequence of SEQ ID No. 1 and a dapA gene promoter sequence having the nucleic add sequence of SEQ ID No. 2 driving transcription of the dapA protein; and further comprising an additional variant protein selected from the following variant proteins: a lysC protein haying the amino add sequence of SEQ ID No. 3, a garb protein encoded by the nucleic add sequence of SEQ. ID No. 4, a yicL protein encoded by the nucleic add sequence of SEQ ID No. 5, a lysP protein having the amino add sequence of SEQ ID No. 6, a mgSA protein encoded by the nucleic add sequence of SEQ ID No. 7, and a pckE protein having the amino add sequence of SEQ ID No. 8.
US Pat. No. 10,918,653

BOVINE MILK OLIGOSACCHARIDES

THE REGENTS OF THE UNIVER...

1. A method of treating gastrointestinal tract microbiota imbalances in an infant, wherein the method comprises administering to the infant a sufficient amount of a composition of Bifidobacterium subsp. infantis or B. breve in or in conjunction with an infant formula,wherein the infant formula comprises one or more of the following fucosylated oligosaccharides as found in bovine milk:
an oligosaccharide consisting of 3 Hexose (Hex) moieties, 4 n-acetyl hexosamine (HexNAc) moieties and 1 fucose (Fuc) moiety;
an oligosaccharide consisting of 4 Hex moieties, 4 HexNAc moieties, and 1 Fuc moiety;
an oligosaccharide consisting of 3 Hex moieties, 5 HexNAc moieties, and 1 Fuc moiety;
an oligosaccharide consisting of 5 Hex moieties, 4 HexNAc moieties, and 1 Fuc moiety;
an oligosaccharide consisting of 4 Hex moieties, 5 HexNAc moieties, and 1 Fuc moiety; and
an oligosaccharide consisting of 3 Hex moieties, 6 HexNAc moieties, and 1 Fuc moiety;
and wherein the composition stimulates the production of a bifidobacterial secretion that reduces colonization of enteropathogenic bacteria in the gut of the infant; modulates signals generated by enteroendocrine and gut epithelial cells in the infant; improves at least one biomarker of gut health in the infant; and/or increases gut colonization and persistence of probiotic bacteria in the infant gut.
US Pat. No. 10,919,934

COMPOSITIONS AND METHODS FOR MANAGING RESPIRATORY CONDITIONS

Emory University, Atlant...

1. A peptide consisting of SEQ ID NO: 1 (EFYDP), esters or salts thereof, wherein proline (P) is a D-isomer or an L-isomer, aspartic acid (D) is a D-isomer or an L-isomer, tyrosine (Y) is a D-isomer or an L-isomer, phenylalanine (F) is a D-isomer or an L-isomer, and glutamic acid (E) is a D-isomer or an L-isomer; andwherein glutamic acid (E) comprises an N-terminal alkanoyl group.
US Pat. No. 10,920,190

FOLDING BIOLOGICAL TISSUE VIA PROGRAMMED CELLULAR CONTRACTILITY

The Regents of the Univer...

1. A method of making a planar biological tissue configured for folding into a three-dimensional shape, the method comprising:patterning contractile cells on a surface of a first and second substrate, comprising:
disposing a pattern of nucleic acids on a first surface of the first substrate and a first surface of the second substrate, wherein the first surface of the first substrate is spaced apart from the first surface of the second substrate via a gap between the first and second substrates and wherein the surfaces are in a facing configuration to each other; and
contacting the patterned nucleic acids under hybridization conditions with a suspension of the contractile cells, wherein the contractile cells comprise cell surface-attached nucleic acids complementary to the patterned nucleic acids, and wherein the cell surface-attached nucleic acids hybridize to the patterned nucleic acids to generate patterned contractile cells on the first surface of the first substrate and the first surface of the second substrate;
contacting the patterned contractile cells on the surfaces of the substrates with a polymer matrix comprising fibers thereby embedding the patterned contractile cells into the polymer matrix;
removing the polymer matrix from between the first and second substrates thereby generating a planar biological tissue comprising the patterned contractile cells on a top surface and a bottom surface of the planar biological tissue, wherein the patterned contractile cells are retained in the polymer matrix upon removal thereby generating a planar biological tissue configured for folding into a three-dimensional shape;
contacting the planar biological tissue with a culture medium; and
incubating the planar biological tissue in suspension in the culture medium for a period of time sufficient for action of the contractile cells on the fibers for folding the tissue into a three-dimensional shape.
US Pat. No. 10,918,654

RUTIN COMPOSITIONS

ALPS Pharmaceutical Ind. ...

1. A water-soluble composition comprising rutin, L-arginine, and an alkali salt of ascorbic acid, wherein a molar ratio between the rutin, L-arginine, and the alkali salt of ascorbic acid is 1:1.6-3.0:0.1-0.46.
US Pat. No. 10,919,935

ANTIMICROBIAL PEPTIDE DERIVED FROM MYXINIDIN PEPTIDE AND USES THEREOF

INDUSTRY-ACADEMIC COOPERA...

1. An antimicrobial peptide having the amino acid sequence of SEQ ID NO: 1,wherein i) the 1st and the 3rd amino acids are substituted with lysine (K) or arginine (R), ii) the 7th and the 10th amino acids are optionally substituted with arginine (R), and iii) the 4th, the 9th, and the 11th amino acids are substituted with tryptophan (W).
US Pat. No. 10,920,191

METHODS OF SCREENING EMBRYONIC PROGENITOR CELL LINES

LINEAGE CELL THERAPEUTICS...

1. An isolated clonal progenitor cell line expressing EYA4, ADH1A and ADH1B, wherein the clonal progenitor cell line is an in vitro human pluripotent stem cell-derived embryonic cutaneous progenitor cell line and wherein the clonal progenitor cell line is encapsulated in a biomaterial.
US Pat. No. 10,918,655

STIMULATING PLATELET GENERATION BY ACTIVATING MITOCHONDRIAL BIOGENESIS

THE GENERAL HOSPITAL CORP...

1. A method of stimulating platelet formation in a subject by administering an effective amount of a drug that stimulates mitochondrial biogenesis to the subject, wherein the mitochondrial biogenesis stimulating drug is selected from the group consisting of bezafibrate, rosiglitazone, pioglitazone, fenofibrate, 5-aminoimidazole-4-carboxyamide-1-beta-D-ribofuranoside (AICAR), metformin, resveratrol, SRT1720, SRT2183, SRT1460, and quercetin.
US Pat. No. 10,919,936

STAPLED AND STITCHED POLYPEPTIDES AND USES THEREOF

President and Fellows of ...

1. A stapled peptide comprising a staple, wherein the staple comprises a carbamate moiety or a tertiary amine moiety.
US Pat. No. 10,920,192

ISOLATED NAIVE PLURIPOTENT STEM CELLS AND METHODS OF GENERATING SAME

Yeda Research and Develop...

1. A method of generating a naive human or monkey pluripotent stem cell (PSC), comprising:(a) obtaining a non-naive human or rhesus monkey PSC;
(b) incubating said non-naive human or said non-naive rhesus monkey PSC in a culture medium comprising an ERK1/2 inhibitor at a concentration of 0.8-3 ?M, a GSK3 beta inhibitor at a concentration of 0.2-3 ?M, a p38 inhibitor at a concentration of 0.05-10 ?M, a JNK inhibitor at a concentration of 1-20 ?M, leukemia inhibitory factor (LIF) at a concentration of 0.5-1000 ng/ml, basic fibroblast growth factor (bFGF) at a concentration of 1-100 ng/ml, and at least one agent selected from the group consisting of: transforming growth factor beta 1 (TGF?1) at a concentration of 0.1-100 ng/ml or an activator thereof, a protein kinase C (PKC) inhibitor at a concentration of 0.5-100 ?M, a ROCK inhibitor at a concentration of 0.1-50 ?M and a NOTCH inhibitor at a concentration of 0.05-50 ?M; under conditions which allow generation of the naive human or the naive rhesus monkey PSC from said non-naive human or said non-naive rhesus monkey PSC,
(c) identifying a naive human or a naive rhesus monkey PSC which comprises:
(1) an unmethylated promoter of the X-inactive specific transcript (XIST) gene, wherein:
(i) when said naive human or rhesus monkey PSC is a female PSC, then said naïve female human or rhesus monkey PSC has two unmethylated alleles of said promoter of said XIST gene; and
(ii) when said naive human or rhesus monkey PSC is a male PSC, then said naïve male human or rhesus monkey PSC has an unmethylated allele of said promoter of said XIST gene,and(2) an expression level of transcription factor E3 (TFE3) in said naive human or rhesus monkey PSC is characterized by a nucleus to cytoplasm expression ratio which is equal to or higher than 1 as determined by an immunostaining assay,
thereby generating the naive human or a naive rhesus monkey PSC.
US Pat. No. 10,918,656

THERAPEUTIC AGENT FOR DRY EYE CHARACTERIZED BY BEING APPLIED TO EYE OF DRY EYE PATIENT WEARING SOFT CONTACT LENS

SANTEN PHARMACEUTICAL CO....

1. A method of ameliorating eye dryness or eye discomfort caused by wearing soft contact lens comprising administering an ophthalmic solution which comprises a therapeutically effective amount of diquafosol or a salt thereof alone as a sole active ingredient and does not comprise benzalkonium chloride to an eye wearing soft contact lens, wherein a concentration of the diquafosol or a salt thereof is 3% (w/v) and the solution comprises a buffer, an isotonicity agent, a stabilizer and a pH adjuster.
US Pat. No. 10,920,193

METHODS FOR EFFICIENT DERIVATION OF HUMAN MOTOR NEURONS FROM DIVERSE SPINAL REGIONS

Wisconsin Alumni Research...

1. A method for generating motor neuron progenitor cells, comprising the steps of:i. culturing an adherent monolayer of SOX2+ and Brachyury+ neuromesodermal progenitor cells in a neural differentiation base medium that comprises FGF and a first concentration of a Wnt/?-catenin signaling pathway agonist for about 4 days;
ii. transiently exposing the cultured cells of (i) to a second concentration of the Wnt/?-catenin signaling pathway agonist for about 6 hours whereby NKX6.1+ ventral progenitor cells are obtained, wherein the second concentration is at least two times greater than the first concentration;
iii. replacing the neural differentiation base medium comprising the second higher concentration of the Wnt/?-catenin signaling pathway agonist with a neural differentiation base medium supplemented with a retinoid and at least one sonic hedgehog (SHH) signaling pathway agonist and lacking any Wnt/?-catenin signaling pathway agonist; and
iv. culturing the NKX6.1+ ventral progenitor cells in the neural differentiation base medium of (iii) for about 2 days whereby a cell population comprising at least 80% OLIG2+ motor neuron progenitors, at least 95% NKX6.1+ motor neuron progenitors, and at least 95% Pax6+ motor neuron progenitors is obtained about 6 days from the start of step (i).
US Pat. No. 10,920,194

FUNCTIONAL MYELINATION OF NEURONS

UNIVERSITY OF MARYLAND, B...

1. A method of producing a functional myelin sheath on one or more neurites of neurons that lack a functional myelin sheath, comprising contacting the neurons with isolated myelin-depositing cells which:(a) are CD34(+) melanocyte stem cells from the bulge region, the lower permanent portion, or both, of the hair follicle of a mammal that have been exposed to neural crest differentiation medium also containing 10 ?M ascorbic acid;
(b) have no visible pigmentation;
(c) express glial fibrillary acid protein, and Tuj1 (?3-tubulin); and
(d) express myelin basic protein and produce a functional multilayered myelin sheath surrounding the neurites of unmyelinated neurons when contacted with the unmyelinated neurites,
wherein contacting is achieved by co-culturing the CD34(+) multipotent neural crest progenitor cells and neurons that lack a functional myelin sheath together in poly-D-lysine and laminin-coated vessels in neural crest differentiation medium including 10 ?M ascorbic acid.
US Pat. No. 10,918,658

COMPOSITIONS AND METHODS FOR ALTERING TISSUE SPECIFICITY AND IMPROVING AAV9-MEDIATED GENE TRANSFER

The Trustees of the Unive...

1. A recombinant adeno-associated virus (AAV) 9 (AAV9) viral particle modified to substantially decrease or ablate the native ability of wild-type (wt) AAV9 to transduce conducting airway, said viral particle having an AAV9 capsid protein in which a native AAV9 amino acid selected from the group consisting of position 271, 446, or 470 based on the positions of SEQ ID NO: 1, is substituted by another amino acid.
US Pat. No. 10,919,939

MU OPIOID RECEPTOR AGONIST ANALOGS OF THE ENDOMORPHINS

The Administrators of the...

1. A cyclic peptide of Formula I:H-Tyr-cyclo[X1-X2-X3-X4]-X5  (I), and salts thereof,whereinX1 is a basic D-amino acid;
X2 is Trp;
X3 is an aromatic amino acid;
X4 is an acidic amino acid;
X5 is selected from the group consisting of Ala-NHR, Arg-NHR, Asn-NHR, Asp-NHR, Cys-NHR, Glu-NHR, Gln-NHR, Gly-NHR, His-NHR, Ile-NHR, Leu-NHR, Met-NHR, Orn-NHR, Phe-NHR, Pro-NHR, Ser-NHR, Thr-NHR, Trp-NHR, Tyr-NHR, and Val-NHR, wherein R is H or an alkyl group; and
there is an amide bond between an amino group and a carboxylic acid group on side chains of amino acids X1 and X4.
US Pat. No. 10,920,195

METHODS TO GENERATE EPITHELIAL CELLS

University of Iowa Resear...

1. A method of generating a re-programmed differentiated mammalian dental epithelial cell comprising(a) transfecting a mammalian oral epithelial cell or a mammalian odontoblast mesenchymal cell via electroporation or Lipofectin with a vector comprising a nucleic acid encoding Pitx2 to form a de-differentiated cell, and
(b) transfecting the de-differentiated cell via electroporation or Lipofectin with a vector comprising a promoter operably linked to a nucleic acid encoding a miR-200a-3p to form a re-programmed differentiated epithelial cell, and
(c) culturing the re-programmed differentiated epithelial cell to generate a mammalian dental epithelial cell that expresses amelogenin.
US Pat. No. 10,918,659

COMPOSITIONS AND METHODS OF ALOE POLYSACCHARIDES

Bespoke Bioscience, LLC, ...

1. A method for the treatment of one or more cancers, wherein the one or more cancers are selected from the group consisting of leukemias and lymphomas, prostate cancer, breast cancer, and colon cancer, comprising the steps of:identifying an individual in need of treatment against the one or more cancers; and
injecting a sterile injectable polymannan extract formulation from Aloe vera two to three times in a week in a dosage sufficient to treat the one or more cancers, wherein the sterile injectable polymannan extract formulation has a molecular weight of 66,000 to 2,000,000 Daltons, and comprises an amount of the polymannan extract formulation is sufficient to treat the leukemias and lymphomas, prostate cancer, breast cancer, and colon cancer specified quantity of very fine polymannan extract dissolved in deionized water; and one or more pharmaceutical preservatives.
US Pat. No. 10,919,940

CYCLIC PEPTIDE FOR TREATING CANCER

Saint Leo University, Sa...

1. A cyclic peptide selected from the group consisting of:(a) the amino acid sequence consisting of the peptide of SEQ ID NO: 1 (Lys-Gly-Glu-Val-Leu-Gln-Met-Glu-Asp-Asp-Leu-Val);
(b) the amino acid sequence consisting of the peptide of SEQ ID NO: 3 (Lys-X5-Glu-X1-X2-Gln-Met-Glu-Asp-Asp-X3-X4) wherein X5 is glycine and X1, X2, X3, and X4 are each independently valine, leucine, isoleucine, or alanine; and
(c) the amino acid sequence consisting of the peptide of SEQ ID NO: 10 (X10-X5-X6-Val-Leu-Gln-Met-Glu-Asp-X9-X3-X4) wherein X10 is arginine, X5 is glycine, X6 is glutamic acid, X9 is aspartic acid, X3 is leucine, and X4 is valine,
wherein the peptide is circularized by forming an amide bond between an N-terminal amino acid and a C-terminal amino acid.
US Pat. No. 10,920,196

METHOD FOR SCALABLE SKELETAL MUSCLE LINEAGE SPECIFICATION AND CULTIVATION

The Curators of the Unive...

1. An in vitro method for producing a cultured meat product for dietary consumption, the method comprising:modifying a porcine induced pluripotent stem cell line comprising pluripotency genes POU5F1 and KLF4 with an inducible MYOD1 transcription factor to produce an inducible MYOD1-transcription-factor-modified porcine cell line;
inducing myogenic differentiation of said modified cell line by exogenous regulation, comprising contacting said modified cell line with an activator of canonical WNT signaling, an inducer of MYoD1 expression, and an inhibitor of DNA methylation, wherein the inhibitor is 5-Aza-Cytidine or 5-Aza-2?-deoxycytidine, wherein the differentiated modified cell line forms myocytes and multinucleated myotubes, both comprising myonuclei, and wherein greater than 50% of the total myonuclei are within the multinucleated myotubes; and
culturing the myocytes and multinucleated myotubes to generate skeletal muscle fibers, thereby producing a cultured meat product for dietary consumption.
US Pat. No. 10,918,660

COMBINATION AND BALANCED NUTRITIOUS FOOD FOR IMPROVING INTESTINAL MICRO-ECOLOGY AND PREVENTING CHRONIC DISEASE, AND APPLICATION THEREOF

BEIJING RUIQIAN SCIENCE A...

1. A combination for improving intestinal micro-ecology and preventing chronic diseases,comprising:
an inulin,
a galactooligosaccharide,
a polydextrose,
an insoluble dietary fiber, and
at least one enhancer comprising at least one of xylooligosaccharide, L-arabinose, stachyose, guar gum, wherein a ratio of the inulin, the galactooligosaccharide, the polydextrose and the insoluble dietary fiber in a formula is 3.5:4:3.5:4.
US Pat. No. 10,920,197

STROMAL STEM CELLS

Orbsen Therapeutics Limit...

1. A method of treating a lung disease in an individual comprising administering to the individual a composition comprising a population of at least 10?6 mammalian stromal stem cells and a pharmaceutically acceptable carrier, wherein 30% or more of the cells are positive for SDC2.
US Pat. No. 10,918,661

SKIN COMPOSITIONS AND METHODS OF USE THEREOF

Shiseido Company, Limited...

1. A therapeutic formulation for the formation of a film over the skin of a subject, comprising a reactive reinforcing component comprising a reactive constituent comprising at least one vinyl terminated organopolysiloxane and at least one hydride functionalized polysiloxane, wherein the reactive reinforcing component has a vinyl to functional hydride molar ratio of between about 1:35 and about 1:100.
US Pat. No. 10,919,942

THERAPEUTIC COMPOSITIONS AND METHODS FOR ANTIBODY AND FC-CONTAINING TARGETING MOLECULE-BASED TARGETED DELIVERY OF BIOACTIVE MOLECULES BY BACTERIAL MINICELLS

VAXIION THERAPEUTICS, LLC...

1. A method of treating cancer in a subject, comprising administering to a subject, optionally a human subject, suffering from cancer a composition comprising a bacterial minicell, wherein the bacterial minicell comprises:(i) an Fc-binding fusion protein displayed on the surface of the minicell, wherein the Fc-binding fusion protein comprises a) an outer membrane anchoring domain and b) an Fc-binding portion of Protein A, wherein the Fc-binding portion of Protein A has no F(ab?)2 binding capability and comprises no cleavage sites by OmpT protease;
(ii) one or more bioactive molecules; and
(iii) one or more Fc-containing targeting molecules bound to said Fc-binding portion, wherein the one or more Fc-containing targeting molecules recognize a eukaryotic antigen.
US Pat. No. 10,920,198

DELTA133P53BETA AND DELTA133P53GAMMA ISOFORMS ARE BIOMARKERS OF CANCER STEM CELLS

Centre National de la Rec...

1. A method for inhibiting the formation of cancer stem cells promoted by a topoisomerase II inhibitor, comprising administering to a subject in need thereof a topoisomerase II inhibitor in combination with an agent reducing ?133p53? isoform, ?133p53? isoform, or both ?133p53? and ?133p53? isoforms expression, wherein the agent reducing ?133p53? isoform, ?133p53? isoform, or both ?133p53? and ?133p53? isoforms expression inhibits formation of cancer stem cells promoted by said topoisomerase II inhibitor.
US Pat. No. 10,919,943

MUTANT PROTEINS ENABLING AGROCHEMICAL CONTROL OF PLANT GENE EXPRESSION

The Regents of the Univer...

1. A plant or a cell comprising a heterologous expression cassette, the expression cassette comprising a promoter operably linked to one or more polynucleotides encoding a first polypeptide comprising a mutated PYR/PYL receptor polypeptide and a second polypeptide comprising a mutated type 2C protein phosphatase (PP2C), wherein the mutated PYR/PYL receptor polypeptide is agonized by an orthogonal ligand that does not significantly agonize a wild-type PYR/PYL receptor polypeptide and wherein the mutated PYR/PYL receptor polypeptide comprises one or more mutations that disrupts binding to a wild-type PP2C, wherein the mutated PP2C comprises one or more mutations that disrupts binding to a wild-type PYR/PYL receptor polypeptide, and wherein the mutated PYR/PYL receptor polypeptide and the mutated PP2C interact with each other, wherein the mutated PYR/PYL receptor polypeptide is at least 95% identical to SEQ ID NO:1 and the mutated PP2C is at least 95% identical to SEQ ID NO:22, and wherein:(a) the mutated PYR/PYL receptor polypeptide comprises a mutation corresponding to F61K in SEQ ID NO:1 and the mutated PP2C comprises a mutation corresponding to V393Q in SEQ ID NO:22;
(b) the mutated PYR/PYL receptor polypeptide comprises a mutation corresponding to S85P in SEQ ID NO:1 and the mutated PP2C comprises a mutation corresponding to E203D in SEQ ID NO:22;
(c) the mutated PYR/PYL receptor polypeptide comprises a mutation corresponding to S85P in SEQ ID NO:1 and the mutated PP2C comprises a mutation corresponding to E203T in SEQ ID NO:22;
(d) the mutated PYR/PYL receptor polypeptide comprises a mutation corresponding to S85P in SEQ ID NO:1 and the mutated PP2C comprises a mutation corresponding to E203W in SEQ ID NO:22;
(e) the mutated PYR/PYL receptor polypeptide comprises a mutation corresponding to T156P in SEQ ID NO:1 and the mutated PP2C comprises a mutation corresponding to I383G in SEQ ID NO:22;
(f) the mutated PYR/PYL receptor polypeptide comprises a mutation corresponding to T162D in SEQ ID NO:1 and the mutated PP2C comprises a mutation corresponding to V393K in SEQ ID NO:22; or
(g) the mutated PYR/PYL receptor polypeptide comprises a mutation corresponding to T162D in SEQ ID NO:1 and the mutated PP2C comprises a mutation corresponding to V393R in SEQ ID NO:22.
US Pat. No. 10,920,199

REPROGRAMMING PROGENITOR COMPOSITIONS AND METHODS OF USE THEREFORE

SALK INSTITUTE FOR BIOLOG...

1. A method of obtaining a reprogrammed murine induced pluripotent stem cell, the method comprising: (a) transducing mouse embryonic fibroblast progenitor cells with one or more viral vectors comprising polynucleotides encoding expressing Oct4, Sox2, Klf4 and cMyc reprogramming factors; (b) inducing in the cells a transient oxidative burst comprising an at least 2-fold increase in oxidative phosphorylation and metabolicactivity and an increased level of at least one analyte selected from nicotinamide adenine dinucleotide (NADH), a ketoglutarate, cellular ATP, ATP synthase in mitochondria (ATP5G1), succinate dehydrogenase (SDHB), isocitrate dehydrogenase (IDH3), NADH dehydrogenase (NDUFA2), superoxide dismutase 2 (SOD2), NADPH oxidase 4 (NOX4), or catalase (CAT) by transducing the mouse embryonic fibroblast progenitor cells with a viral vector comprising a polynucleotide encoding estrogen related receptor gamma (ERR?) and expressing ERR? in the cells 3-5 days following step (a), wherein the expression of ERR? in the cells results in the upregulation of at least one ERR? cofactor selected from Peroxisome proliferator-activated receptor Gamma Coactivator 1 alpha (PGC-1?) or Peroxisome proliferator-activated receptor Gamma Coactivator 1 beta (PGC-1?) in the cells, thereby facilitating reprogramming and inducing pluripotency in the cells; (c) obtaining a reprogrammed murine induced pluripotent stem cell; and, (d) optionally, isolating said reprogrammed murine induced pluripotent stem cell from the culture.
US Pat. No. 10,918,663

COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL VAGINOSIS

REOXCYN, LLC, South Jord...

1. A method of promoting vaginal health in a subject, comprising:topically administering to a vaginal region of a subject a composition comprising:
a reactive oxygen species;
a rheology agent;
a silicone polymer; and
hydrochloric acid,
wherein the composition has a pH ranging from about 6.0 to about 7.5,
whereby, topically administering the composition promotes a healthy vaginal microenvironment by maintaining healthy vaginal microbiota.
US Pat. No. 10,919,944

FILARIAL NEMATODE VACCINES, POLYPEPTIDES, AND NUCLEIC ACIDS

The University of Liverpo...

1. A polypeptide comprising:at least one ShK domain of L. sigmoidontis protein nLs_04059 according to SEQ ID NO:1; and/or
at least one polypeptide sharing at least 70 percent identity with said at least one ShK domain, wherein the at least one polypeptide retains 6 cysteine residues with characteristic spacing of an ShK domain;
wherein the polypeptide is artificial.
US Pat. No. 10,920,200

GLUCOSE OXIDASE CNGODA AND GENE AND APPLICATION THEREOF

FEED RESEARCH INSTITUTE, ...

1. A method of producing glucose oxidase having the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, comprising the steps of:(1) transforming a prokaryotic or eukaryotic host cell in culture with a polynucleotide comprising a nucleotide sequence encoding said glucose oxidase to obtain a recombinant host cell;
(2) cultivating the recombinant host cell to induce expression of said glucose oxidase; and
(3) isolating and recovering said glucose oxidase.
US Pat. No. 10,918,664

CHEWABLE EYE HEALTH FORMULATION

1. A chewable tablet consisting of natural flavor, 250 mg vitamin C consisting of both ascorbic acid and sodium ascorbate, 200 international units vitamin E, 12.5 mg zinc from zinc oxide, 1.0 mg copper from copper citrate, 5 mg lutein and 1 mg zeaxanthin.
US Pat. No. 10,919,945

MODULAR ANTIGEN TRANSPORTATION MOLECULES AND USES THEROF

1. A method of preventing and/or treatment of insect bite hypersensitivity (IBH), urticaria or combinations thereof in equines, comprising administering a pharmaceutically effective amount of an improved Modular Antigen Transportation (iMAT) molecule comprising:(a) at least one first module being an amino acid sequence allowing the translocation of the iMAT molecule from the extracellular space into the interior of cells, wherein the at least one first module is selected from: (i) the amino acid sequence of HIV-tat, VP22, and/or Antennapedia, or (ii) the amino acid sequence according to SEQ ID NO: 1;
(b) at least one second module being an amino acid sequence allowing species-specific intracellular targeting of the iMAT molecule to the cell organelles which are involved in the processing of antigens and/or the loading of MHC molecules with antigens, wherein such at least one second module comprises one of the amino acid sequences selected from: SEQ ID NOS: 2, 15, 16; and
(c) at least one third module as antigen module being an amino acid sequence derived from at least one epitope of at least one antigen, wherein such at least one antigen is an allergen derived from blood feeding insects from the genus Culicoides,
 characterized in that in the entire iMAT molecule all cysteine residues are substituted with a different amino acid residue.
US Pat. No. 10,920,201

RICE EPSPS MUTANT, ENCODING GENE AND USE THEREOF

GEVOTO LLC, Chengdu (CN)...

1. A rice 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS) mutant, wherein said rice EPSPS mutant comprises the amino acid sequence of SEQ ID NO. 1.
US Pat. No. 10,918,665

CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND USES THEREOF

MEMORIAL SLOAN KETTERING ...

1. A chimeric antigen receptor (CAR), comprising an extracellular antigen-binding domain that binds to B cell maturation antigen (BCMA), a transmembrane domain, and an intracellular domain, wherein the extracellular antigen-binding domain comprises:(a) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:1, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:2;
(b) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:5, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:6;
(c) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:9, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:10;
(d) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:13, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:14;
(e) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:17, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:18;
(f) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:21, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:22;
(g) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:25, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:26;
(h) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:29, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:30;
(i) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:33, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:34;
(j) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:37, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:38;
(k) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:41, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:42;
(l) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:45, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:46;
(m) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:49, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:50;
(n) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:53, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:54;
(o) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:57, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:58;
(p) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:61, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:62; or
(q) a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 of the heavy chain variable region sequence set forth in SEQ ID NO:65, and a light chain variable region comprising a CDR1, a CDR2, and a CDR3 of the light chain variable region sequence set forth in SEQ ID NO:66.
US Pat. No. 10,919,946

CHIMERIC MOLECULE USEFUL IN IMMUNOTHERAPY FOR LEISHMANIASIS, WHICH INCLUDES A FRAGMENT OF THE PFR1 PROTEIN OF LEISHMANIA INFANTUM WITH SPECIFIC IMMUNODOMINANT EPITOPES

1. A method for prevention of kinetoplastid infections that cause leishmaniasis disease in an animal, comprising, use of an expression product of at least one nucleotide sequence selected from the group consisting of:a nucleotide sequence coding for the PFR1 protein of Leishmania infantum or a fragment thereof comprising at least one immunodominant epitope selected from the eptitope group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, wherein the immunodominant epitope is able to induce an antigen-specific T cell cytotoxic immune response against the kinetoplastids causing leishmaniasis disease in an animal;
a nucleotide sequence coding for the 1-595 amino acids of Leishmania infantum PFR1 protein, determined by the SEQ ID NO:12, and comprising at least one immunodominant epitope able to induce an antigen-specific T cell cytotoxic immune response against kinetoplastids causing leishmaniasis disease in an animal;
a nucleotide sequence coding for the 160-595 amino acids of Leishmania infantum PFR1 protein, determined by the SEQ ID NO:9, and comprising at least one immunodominant epitope able to induce an antigen-specific T cell cytotoxic immune response against kinetoplastids causing leishmaniasis disease in an animal;
a nucleotide sequence coding for the 160-548 amino acids of Leishmania infantum PFR1 protein, determined by the SEQ ID NO:10, and comprising at least one immunodominant epitope able to induce an antigen-specific T cell cytotoxic immune response against kinetoplastids causing leishmaniasis disease in an animal; and
a nucleotide sequence coding for the 160-385 amino acids of Leishmania infantum PFR1 protein, determined by the SEQ ID NO:11, and comprising at least one immunodominant epitope able to induce an antigen-specific T cell cytotoxic immune response against kinetoplastids causing leishmaniasis disease in an animal.
US Pat. No. 10,920,202

THERMOLABILE SERRATIA MARCESCENS NUCLEASE

AbClonal Science, Inc., ...

1. A thermolabile Serratia Marcescens Nuclease mutant, comprising: the amino acid sequence of SEQ ID NO: 12 not including the first 21 amino acids from the N-terminus.
US Pat. No. 10,918,666

PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY

Iovance Biotherapeutics, ...

1. A method for expanding tumor infiltrating lymphocytes (TILs) into a therapeutic population of TILs comprising:(a) obtaining a first population of TILs from a tumor resected from a patient by processing a tumor sample obtained from the patient into multiple tumor fragments;
(b) adding the tumor fragments into a closed system;
(c) performing a first expansion by culturing the first population of TILs in a cell culture medium comprising IL-2, and optionally OKT-3, to produce a second population of TILs, wherein the first expansion is performed in a closed container providing a first gas-permeable surface area, wherein the first expansion is performed for about 3-14 days to obtain the second population of TILs, wherein the transition from step (b) to step (c) occurs without opening the system;
(d) performing a second expansion by supplementing the cell culture medium of the second population of TILs with additional IL-2, optionally OKT-3, and antigen presenting cells (APCs), to produce a third population of TILs, wherein the second expansion is performed for about 4-6 days to obtain the third population of TILs, wherein the second expansion is performed in a closed container providing a second gas-permeable surface area, and wherein the transition from step (c) to step (d) occurs without opening the system;
(e) dividing the third population of TILs into a first plurality of 2-5 subpopulations of TILs, wherein at least 1.0×109 TILs are present in each subpopulation, wherein the transition from step (d) to (e) occurs without opening the system;
(f) performing a third expansion of the first plurality of subpopulations of TILs by supplementing the cell culture medium of each subpopulation of TILs with additional IL-2, optionally OKT-3, to produce a second plurality of subpopulations of TILs, wherein the third expansion is performed for about 5-7 days, wherein the third expansion for each subpopulation is performed in a closed container providing a third gas-permeable surface area, and wherein the transition from step (e) to step (f) occurs without opening the system;
(g) harvesting the second plurality of subpopulations of TILs obtained from step (f), wherein the transition from step (f) to step (g) occurs without opening the system; and
(h) transferring the harvested subpopulations of TILs from step (g) to one or more infusion bags, wherein the transition from step (g) to (h) occurs without opening the system.
US Pat. No. 10,919,947

PHARMACEUTICAL COMPOSITION CONTAINING, AS ACTIVE INGREDIENT, FUSION PROTEIN IN WHICH TUMOR-PENETRATING PEPTIDE AND ANTI-ANGIOGENESIS AGENT ARE FUSED, FOR PREVENTING AND TREATING CANCER OR ANGIOGENESIS-RELATED DISEASES

IL DONG PHARMACEUTICAL CO...

1. A composition comprising, as an active ingredient, a fusion protein obtained by fusion of a tumor-penetrating peptide and an anti-vascular endothelial growth factor (anti-VEGF) agent, wherein the tumor-penetrating peptide comprises the amino acid of SEQ ID NO: 1 or SEQ ID NO: 2, and the anti-VEGF agent is selected from the group consisting of ranibizumab, bevacizumab, aflibercept, conbercept, r84, CT01, DOM15-10-11, DOM15-26-593, PRS-050, CT-322, ESBA903, and EPI-0030.
US Pat. No. 10,920,203

METHODS OF REDUCING ODOR

1. A lipase variant having lipase activity and having between 90% to less than 100% sequence identity to a parent lipase comprising the mature polypeptide of SEQ ID NO: 2, SEQ ID NO:4, SEQ ID NO: 6, SEQ ID NO:8, SEQ ID NO: 10, or SEQ ID NO: 12, wherein the variant comprises V228P using SEQ ID NO:10 or SEQ ID NO: 2 for position numbering.
US Pat. No. 10,918,667

MODIFIED CELL EXPRESSING THERAPEUTIC AGENT AND USES THEREOF

Innovative Cellular Thera...

1. A pharmaceutical composition, wherein the pharmaceutical composition comprises modified T cells comprising a first nucleic acid encoding a chimeric antigen receptor (CAR) and a second nucleic acid encoding therapeutic agents IL-6 and IFN-? and comprising SEQ ID NO: 469.
US Pat. No. 10,919,948

RECOMBINANT POLYPEPTIDES, COMPOSITIONS, AND METHODS THEREOF

BioGend Therapeutics Co.,...

1. A biodegradable composition, comprising:a recombinant polypeptide comprising:
a first domain selected from the group consisting of SEQ ID NO: 35 and SEQ ID NO: 39;
a second domain selected from the group consisting of SEQ ID NO: 47 and SEQ ID NO: 49; and
a third domain selected from the group consisting of SEQ ID NO: 57 and SEQ ID NO: 61;
wherein the first domain is fused to either C-terminal or N-terminal of the second domain, the third domain is fused to the second domain or the first domain, and wherein the second domain comprises an intramolecular disulfide bond and the recombinant polypeptide is capable of inducing alkaline phosphatase activity; and
a biodegradable calcium phosphate carrier having a plurality of pores.
US Pat. No. 10,920,204

COMPOSITIONS AND METHODS COMPRISING A LIPOLYTIC ENZYME VARIANT

DANISCO US INC, Palo Alt...

1. A lipolytic enzyme variant or an active fragment thereof comprising an amino acid modification to a parent lipolytic enzyme, wherein the modification is at a productive position of the lipolytic enzyme variant, wherein at least one modification of the modifications tested at the productive position meet at least one of the following criteria:a) a position wherein the minimum performance indices (PI) relative to Thermomyces lanuginosus lipase (TLL) parent for expression, Cotton Soils 61 (CS-61) micro-swatch activity at pH 8.2, activity on p-Nitrophenyl ester substrates at pH 6 or pH 8.2, and detergent stability, Sodium linear C11-13 alkyl benzenesulfonate (LAS) stability or thermostability are greater than or equal to 0.9, and in addition have a PI for any one of these tests that is greater than or equal to 1.0;
b) a position wherein the minimum PI relative to TLL parent for expression, CS-61 micro-swatch activity at pH 8.2, activity on p-Nitrophenyl ester substrates at pH 6 or pH 8.2, and detergent stability, LAS stability or thermostability are greater than or equal to 0.8, and in addition have a PI for any one of these tests that is greater than or equal to 1.2;
c) a position wherein the minimum PI relative to TLL parent for expression, CS-61 micro-swatch activity at pH 8.2, activity on p-Nitrophenyl ester substrates at pH 6 or pH 8.2, and detergent stability, LAS stability or thermostability are greater than or equal to 0.5, and in addition have a PI for any one of these tests that is greater than or equal to 1.5;
wherein the productive position is selected from the group consisting of 11, 18, 24 and 189, wherein the variant has at least 93% amino acid sequence identity to SEQ ID NO:4, with the proviso that the modification at position 11 is not a histidine (H), wherein the amino acid positions of the lipolytic enzyme variant are numbered by correspondence with the amino acid sequence of TLL set forth in SEQ ID NO:4.
US Pat. No. 10,918,668

TARGETED DISRUPTION OF T CELL RECEPTOR GENES USING ENGINEERED ZINC FINGER PROTEIN NUCLEASES

Sangamo Therapeutics, Inc...


and further wherein upon expression of the pair of ZFNs the TRBC gene is inactivated;
(v) a first lentiviral (LV) vector comprising an exogenous sequence encoding a tumor antigen specific TRAC transgene; and
(vi) a second LV vector comprising an exogenous sequence a tumor specific TRBC transgene, wherein upon expression of the ZFN pairs of (iii) and (iv), at least 40% of the T lymphocytes of the isolated population are disrupted at both the TRAC and TRBC genes.
US Pat. No. 10,919,949

ACYLATED INSULIN ANALOGUES AND USES THEREOF

1. An insulin derivative, comprising an insulin analogue comprising B5Y or B5F and a substituent comprising an acyl group, or a pharmaceutically acceptable salt, amide or ester thereof, wherein said insulin analogue further comprises B28K or B26K and said acyl group is attached to B28K or B26K.
US Pat. No. 10,920,205

LIPASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME

1. A lipase variant which has lipase activity, at least 85% but less than 100% sequence identity to SEQ ID NO: 3, and comprises an amino acid substitution at position 1 of SEQ ID NO: 3.
US Pat. No. 10,918,669

METHODS OF TREATING EXERCISE-INDUCED PULMONARY HEMORRHAGE

RECELLERATE, INC., Middl...

1. A method of treating exercise-induced pulmonary hemorrhage in a horse in need thereof, comprising:(i) administering a first amount of a pharmaceutical composition comprising granuloma fluid, or a composition derived therefrom, to the horse, prior to exercise;
(ii) administering a second amount of the pharmaceutical composition comprising granuloma fluid, or a composition derived therefrom, to the horse after exercise,
wherein the granuloma fluid or composition derived therefrom comprises stem cells in an amount of about 5×104 to about 5×1011 cells.
US Pat. No. 10,919,950

TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT

1. A nucleic acid encoding a fusion protein, the nucleic acid comprising:a first polynucleotide encoding an extracellular domain of a mutant PD-1 protein selected from a PD-1 extracellular domain of a protein encoded by the nucleotide sequence of any one of SEQ ID NOs 14, 16 or 17;
a second polynucleotide encoding a spacer; and
a third polynucleotide encoding an interferon-?2 protein;
wherein the fusion protein comprising the extracellular domain of a mutant PD-1 protein is capable of specifically binding to a PD-L1 protein with an increased affinity compared to a fusion protein comprising an extracellular domain of a wild-type PD-1 protein.
US Pat. No. 10,920,206

ACIDIC THERMOPHILIC POLYGALACTURONASE TEPG28A, AND ENCODING GENE AND APPLICATION THEREOF

FEED RESEARCH INSTITUTE, ...

1. A method of producing a polygalacturonase having the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2, comprising the steps of:(1) transforming a prokaryotic or eukaryotic host cell in culture with a polynucleotide comprising a nucleotide sequence encoding said polygalacturonase to obtain a recombinant host cell;
(2) cultivating the recombinant host cell to induce expression of said polygalacturonase; and
(3) isolating and recovering said polygalacturonase.
US Pat. No. 10,918,670

OSTEOINDUCTIVE PUTTIES AND METHODS OF MAKING AND USING SUCH PUTTIES

RTI Surgical, Inc., Alac...

1. A carrier for use in an implantable composition comprising a mixture of thermally denatured collagen fragments,wherein said mixture of thermally denatured collagen fragments has a sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) profile, and said SDS-PAGE profile comprises a region between about 29 kDa and about 97 kDa,
wherein said region is without prominent, intense, or discernable bands as compared to a Type-I collagen reference material, wherein
said SDS-PAGE profile was obtained on standard 12 lane 8-16% gradient pre-made gels through analysis at constant voltage of 100 V for 2.5 h, transferred to nitrocellulose filter and stained with 0.1% ponceau red to confirm protein transfer and mark the position of molecular weight markers; and
wherein said carrier is not a gelatin, does not have a measurable Bloom strength and wherein said SDS-PAGE profile also has a band between about 15 kDa and about 20 kDa; and
wherein said carrier is made from demineralized bone matrix (DBM).
US Pat. No. 10,919,951

CHIMERIC ANTIGEN RECEPTOR

AUTOLUS LIMITED, London ...

1. A chimeric antigen receptor (CAR) which comprises:(i) truncated proliferation-inducing ligand (APRIL) that
(a) binds B cell maturation antigen (BCMA) and
(b) binds transmembrane activator and calcium modulator and cylophilin ligand interactor (TACI);
(ii) a spacer domain; and
(ii) a transmembrane domain; and
(iii) an intracellular T cell signaling domain.
US Pat. No. 10,920,207

HOST CELL CAPABLE OF PRODUCING ENZYMES USEFUL FOR DEGRADATION OF LIGNOCELLULOSIC MATERIAL

DSM IP ASSETS B.V., Heer...

1. A transformed filamentous fungal host cell comprising at least four different heterologous polynucleotides encoding at least four different fungal enzymes selected from the group consisting of fungal cellulases, fungal hemicellulases and fungal pectinases, wherein the transformed filamentous fungal host cell is capable of secreting the at least four different fungal enzymes.
US Pat. No. 10,918,671

METHOD OF CONSTRUCTING MASSES OF MYOCARDIAL CELLS AND USE OF THE MYOCARDIAL CELL MASS

DAIICHI SANKYO COMPANY, L...

1. A method of treating myocardial infarction in a mammal comprising the steps of:a) differentiating isolated mammalian pluripotent stem cells into aggregated cell masses comprising cardiomyocytes;
b) dispersing the aggregated cell masses comprising cardiomyocytes such that single cardiomyocytes are obtained;
c) purifying the single cardiomyocytes of the step b);
d) culturing the purified single cardiomyocytes in a culture medium under serum-free conditions for at least 12 hours such that the single cardiomyocytes form reaggregated masses of cardiomyocytes; and
e) transplanting the reaggregated masses of cardiomyocytes into a site of myocardial infarction in the mammal such that a symptom of the myocardial infarction is treated.
US Pat. No. 10,919,183

METHOD FOR ENGINEERING THREE-DIMENSIONAL SYNTHETIC VASCULAR NETWORKS THROUGH MECHANICAL MICROMACHINING AND MUTABLE POLYMER MICROMOLDING

CARNEGIE MELLON UNIVERSIT...

1. A method for creating a vascularized structure, comprising:milling a groove on a substrate, wherein the groove forms a pattern that mimics a biologic structure;
transferring the pattern from the substrate to a first mold;
transferring the pattern from the substrate to a second mold, wherein the second mold is a mirror image of the first mold;
joining the first mold and second mold together, forming a micromold having a microchannel with a circular cross-section;
flowing a template material into the microchannel,
wherein the micromold has a dissolution rate that prevents dissolution of the micromold during flowing the template material;
causing the template material to solidify in the microchannel;
dissolving the micromold, leaving a template having a shape of the microchannel;
embedding the template in a growth medium;
solidifying the growth medium;
liquefying and then removing the template material, leaving a cavity in the growth medium in the shape of the template; and
perfusing the cavity with cellular material.
US Pat. No. 10,919,952

METHOD FOR PREPARING COLLAGEN AGGREGATE AND COLLAGEN FROM CHROMIUM-CONTAINING TANNED LEATHER WASTES BY COMBINED ACID-ENZYME CONTROLLED DEGRADATION TECHNOLOGY

1. A method for preparing a collagen from a chromium-containing tanned leather waste comprising:(1) acid dechromation: immersing the chromium-containing tanned leather waste in a 1.0-5.0 mol/L hydrochloric acid solution for 0.5-3 hours; washing the chromium-containing tanned leather waste with water for 3-5 times to pH=5-7; placing the chromium-containing tanned leather waste in a 0.1-1.0 mol/L oxalic acid solution, the weight of the oxalic acid solution being 20-50 times of the dry weight of the chromium-containing tanned leather waste; transferring the mixture of the chromium-containing tanned leather waste and the oxalic acid solution to a homogenizer; stirring the mixture in the homogenizer at 30-50° C. for 5-48 hours; centrifuging the mixture at a speed of 5000-20000×g and collecting a first precipitate; dispersing the first precipitate in 0.1-1.0 mol/L sodium oxalate solution, the weight of the sodium oxalate solution being 20-50 times of the dry weight of the chromium-containing tanned leather waste; stirring the mixture of the first precipitate and the sodium oxalate solution at 30-50° C. for 24-120 hours; and centrifuging the mixture at a speed of 5000-20000×g and collecting a second precipitate;
(2) placing the second precipitate in a 0.1-1.0 mol/L acetic acid-citric acid solution, the weight of the acetic acid-citric acid solution being 20-50 times of the dry weight of the chromium-containing tanned leather waste; transferring the mixture of the second precipitate and the acetic acid-citric acid solution to the homogenizer and stirring the mixture; adding a first 0.1-1.0 mol/L sodium hydroxide solution to the mixture to pH=7.0-7.5; adding 1.0 mol/L ammonium sulfate solution to the mixture and salting out for 10-24 hours; centrifuging the mixture at a speed of 5000-20000×g for 15-30 minutes and collecting a third precipitate; dispersing the third precipitate in a first 0.1-1.0 mol/L acetic acid solution, the weight of the acetic acid solution being 20-50 times of the dry weight of the chromium-containing tanned leather waste; dialyzing in distilled water for 10-48 hours and lyophilizing to obtain a collagen aggregate, and
(3) cutting the collagen aggregate; placing the collagen aggregate in a second 0.1-1.0 mol/L acetic acid solution, the weight of the acetic acid solution being 20-50 times of the dry weight of the collagen aggregate; adding a pepsin to the mixture of collagen aggregate and acetic acid solution, the weight of the pepsin being 0.5%-2% of the weight of the collagen aggregate; reacting the mixture in a supercritical carbon dioxide reactor at 40-42° C. and 80-100 atmospheres for 5-24 hours; adding a second 0.1-1.0 mol/L sodium hydroxide solution to the mixture to pH=7.0-7.5; adding a 1.0-1.5 mol/L sodium chloride solution and salting out for 10-24 hours; centrifuging the mixture at a speed of 5000-20000×g for 15-30 minutes and collecting a fourth precipitate; dispersing the fourth precipitate in a 0.1-0.5 mol/L acetic acid solution; dialyzing in distilled water for 10-48 hours and lyophilizing to obtain the collagen.
US Pat. No. 10,920,208

EVOLUTION OF PROTEASES

President and Fellows of ...

1. A mutagenesis plasmid comprising a gene expression cassette encoding:(i) a deoxyadenosine methylase, wherein the methylase is dam;
(ii) a hemimethylated-GATC binding domain, wherein the hemimethylated-GATC binding domain is seqA; and
(iii) a dominant-negative E. coli DNA polymerase III proofreading subunit, wherein the dominant-negative E. coli DNA polymerase III proofreading subunit is dnaQ926; wherein the expression cassette does not encode recA730.
US Pat. No. 10,918,672

SMALL TISSUE CCR5?MSCS FOR TREATMENT OF HIV

THE ADMINISTRATORS OF THE...

1. A method of treating HIV infection, comprising:a. isolating small tissue mesenchymal stem cells (stMSCs) from a patient with HIV, from a syngeneic donor, or from an immuno-compatible donor, wherein the isolating step selects only stMSCs having the phenotype CD11b?CD34?CD45?CD29+CD49+Oct4+SSEA4+, and
wherein said selected stMSCs are i) 4-6 ?m in diameter, and ii) pluripotent;
b. editing the CCR5 gene in said selected stMSCs to provide CCR5?CD11b CD34?CD45?CD29+CD49+Oct4+SSEA4+stMSCs; and
c. re-introducing said CCR5?CD11b CD34?CD45?CD29+CD49+Oct4+SSEA4+stMSCs into said HIV patient.
US Pat. No. 10,919,953

FCGAMMARIIB-SPECIFIC FC REGION VARIANT

Chugai Seiyaku Kabushiki ...

1. A protein comprising an IgG Fc region variant in which the amino acid at position 238 (EU numbering) is Asp, wherein the IgG Fc region variant further comprises one of the following combinations (i) to (xxiv) (all positions by EU numbering):(i) Asp at position 233, Asp at position 237, Asp at position 268, Gly at position 271, Asp at position 296, and Arg at position 330;
(ii) Asp at position 237, Asp or Glu at position 268, Gly at position 271, Asp at position 296, and Arg at position 330;
(iii) Asp at position 233, Asp at position 237, Asp at position 268, Gly at position 271, Asp at position 296, Arg at position 330, and Thr at position 332;
(iv) Asp at position 233, Asp at position 237, Ile at position 264, Gly or Ala at position 267, Glu at position 268, Gly at position 271, and Arg at position 330;
(v) Asp at position 233, Asp at position 237, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 296, Arg at position 330, and Thr at position 332;
(vi) Asp at position 237, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 296, Arg at position 330, and Thr at position 332;
(vii) Asp at position 233, Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, and Gly at position 271;
(viii) Asp at position 233, Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 296, and Arg at position 330;
(ix) Asp at position 233, Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 296, Arg at position 330, and Met or Leu at position 396;
(x) Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, and Arg at position 330;
(xi) Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 296, and Arg at position 330;
(xii) Ile at position 264, Ala at position 267, Glu at position 268, and Gly at position 271;
(xiii) Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, and Asp at position 296;
(xiv) Asp at position 237, Ala or Gly at position 267, Glu at position 268, Gly at position 271, Asp at position 296, and Arg at position 330;
(xv) Asp at position 233, Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Arg at position 330, and Met or Leu at position 396;
(xvi) Asp at position 233, Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 296, Gly at position 327, Arg at position 330, and Met at position 396;
(xvii) Asp at position 233, Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 272, and Asp at position 296;
(xviii) Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Pro at position 272, and Arg at position 330;
(xix) Asp at position 237, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Pro at position 272, Asp at position 296, and Arg at position 330;
(xx) Asp at position 233, Ile at position 264, Ala at position 267, Glu at position 268, and Gly at position 271;
(xxi) Asp at position 237, Gly at position 267, Asp at position 268, Gly at position 271, Asp at position 296, and Arg at position 330;
(xxii) Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, Asp at position 272, Asp at position 296;
(xxiii) Asp at position 233, Ile at position 264, Ala at position 267, Glu at position 268, Gly at position 271, and Asp at position 296; or
(xxiv) Asp at position 233, Tyr at position 234, Phe at position 235, Asp at position 237, Ile at position 264, Glu at position 265, Phe at position 266, Ala at position 267, Asp at position 268, Asp at position 269, Gly at position 271, Asp at position 272, Gln at position 274, Asp at position 296, Ala at position 326, Gly at position 327, Lys at position 330, Ser at position 331, Lys at position 332, Lys at position 333, Arg at position 334, Ala at position 355, Glu at position 356, Met at position 358, Ala at position 396, Arg at position 409, and Glu at position 419.
US Pat. No. 10,920,209

SUBTILASE VARIANTS HAVING IMPROVED STORAGE STABILITY

1. A polypeptide comprising a subtilase variant having protease activity, wherein the amino acid sequence of the variant has at least 82% but less than 100% sequence identity to SEQ ID NO: 1, and wherein the variant comprises the substitution N76D and substitutions in positions 205 and 206, where the substitution in position 205 is V205I or V205L, and the substitution in position 206 is Q206C, Q206E, Q206I, Q206K, Q206I, Q206V, Q206W or Q206L, wherein each position corresponds to the position of the polypeptide of SEQ ID NO: 2 and said positions correspond to N74, V199, and Q200 of SEQ ID NO: 1.
US Pat. No. 10,918,673

IMMUNOISOLATION DEVICE

THE REGENTS OF THE UNIVER...

1. An immunoisolation device consisting of;a) a degradable inner core comprising ovarian tissue or ovarian cells; and
b) a non-degradable external shell encapsulating the degradable inner core.
US Pat. No. 10,919,954

ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING/AVOIDING AND USES THEREOF

Ablynx N.V., Ghent-Zwijn...

1. A liquid pharmaceutical formulation for parenteral administration comprising i) a polypeptide that comprises at least one immunoglobulin single variable domain that binds human serum albumin and consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementary determining regions (CDR1-CDR3, respectively), wherein the CDR1 has the amino acid sequence SFGMS (amino acids 167-171 of SEQ ID NO: 3), the CDR2 has the amino acid sequence SISGSGSDTLYADSVKG (amino acids 186-202 of SEQ ID NO: 3), and the CDR3 has the amino acid sequence GGSLSR (amino acids 235-240 of SEQ ID NO: 3), and ii) sucrose or trehalose, wherein the addition of said sucrose or trehalose results in a reduction of the % of the polypeptides that forms dimers during storage of the liquid formulation at 37° C., the % dimers as measured by SE-HPLC, and wherein the polypeptide does not comprise an Fc fusion.
US Pat. No. 10,918,161

FOOTWEAR SOLE, BOOT AND SANDAL

TOTES ISOTONER CORPORATIO...

1. A boot, comprising:a sole portion;
a lower portion; and
a boot shaft portion,
wherein the sole portion, the lower portion and the boot shaft portion are formed as a unitary member composed of a single compound, and
wherein the single compound includes:
styrene ethylene butylene styrene block copolymer (SEBS)
ethyl vinyl acetate copolymer (EVA) in the range of 17% to 27% by weight; and
polyolefin elastomer (POE) in the range of 6% to 16% by weight.
US Pat. No. 10,918,674

EDIBLE BIRD'S NEST EXTRACT AND METHOD OF EXTRACTION

1. A method for preparing a bird's nest extract, the extract comprising at least one molecule obtained from edible bird's nest (EBN), the method comprising the steps of:(a) washing raw EBN;
(b) filtering the washed EBN;
(c) extracting the molecule from the EBN,
wherein extracting the molecule is carried by exposing the washed EBN to any one of an extraction solution selected from the group consisting of:
(i) a solution comprising an anti-N glycan and an anti-O glycan;
(ii) a solution comprising an anti-heparan sulphate, an anti-chondroitin, an anti-keratan, and an anti-dermatan; and
(iii) a solution comprising an anti-leucine zipper, an anti-helix-turn-helix, and an anti-zinc finger.
US Pat. No. 10,920,211

SERINE PROTEASE MOLECULES AND THERAPIES

Research Development Foun...

1. A cell-targeting polypeptide construct comprising, from N- to C-terminus:(a) a truncated serine protease having an IIGG, IVGG or ILGG at its N -terminus, the truncated serine protease having an amino acid sequence at least 95% identical to a SEQ ID NO: 1, SEQ ID NO: 46, SEQ ID NO:47, SEQ ID NO: 48, SEQ ID NO:49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SE q ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57 or SEQ ID NO: 58;
(b) an antibody heavy chain constant (Fc) domain; and
(c) a cell-targeting hormone domain.
US Pat. No. 10,920,212

MONOMERIC AND FUNCTIONAL ADENYLATE CYCLASE CYAA TOXIN

INSTITUT PASTEUR, Paris ...

1. A method to produce a solution of monomeric, stable and functional CyaA toxin, comprising:A) providing a sample comprising denatured and acylated CyaA toxin, between 4M and 10M of a chaotropic agent, and between 1 and 10 mM of a calcium salt,
B) applying said sample on a size-exclusion chromatography column having a matrix that provides molecular confinement on the CyaA toxin, in the presence of calcium, and
C) eluting the CyaA toxin from the size-exclusion chromatography column with an elution buffer comprising a calcium salt but no chaotropic agent;
to thereby provide a solution of monomeric, stable and functional CyaA toxin that does not contain chaotropic agent.
US Pat. No. 10,918,676

EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF

Aimmune Therapeutics, Inc...

1. A method of manufacturing a packaged pharmaceutical formulation for the treatment of egg allergy in a subject, comprising: a) determining the concentrations of ovomucoid, ovalbumin, and lysozyme proteins in a composition of egg white protein by one or more analytical methods; b) comparing the concentrations of the proteins to the concentrations of a reference standard; c) selecting a composition for treatment of egg allergy in a subject; and d) packaging the selected composition in a container, wherein the selected composition contains at least the concentrations of ovomucoid, ovalbumin, and lysozyme protein as the reference standard.
US Pat. No. 10,919,957

HUMANIZED MONOCLONAL ADVANCED GLYCATION END-PRODUCT ANTIBODY

Siwa Corporation, Chicag...

1. A humanized monoclonal advanced glycation end-product antibody, comprisinga heavy chain, and
a light chain,
wherein the heavy chain comprises an amino acid sequence having at least 90% sequence identity with at least one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5,
the light chain comprises an amino acid sequence having at least 90% sequence identity with at least one amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15, and
the antibody binds a carboxymethyllysine-modified protein or peptide.
US Pat. No. 10,920,213

HEAT-RESISTANT CARBONIC ANHYDRASE MUTANTS AND COMPOSITION FOR CAPTURING CARBON DIOXIDE CONTAINING THE SAME

SK Innovation Co., Ltd., ...

1. A carbonic anhydrase mutant comprising an A58G mutation in the amino acid sequence set forth in SEQ ID NO: 1.
US Pat. No. 10,921,495

SOLAR CONTROL COATINGS AND METHODS OF FORMING SOLAR CONTROL COATINGS

Vitro Flat Glass LLC, Ch...

1. A coated article comprising:a substrate; and
a coating applied over at least a portion of the substrate, the coating comprising:
a first dielectric layer formed over at least a portion of the substrate;
a first metallic layer formed over at least a portion of the first dielectric layer;
a second dielectric layer formed over at least a portion of the first metallic layer;
a second metallic layer formed over at least a portion of the second dielectric layer; and
a third dielectric layer formed over at least a portion of the second metallic layer,
wherein at least one of the metallic layers is formed from a material comprising one or more silver compounds doped with iron and an additional metal selected from Groups 3 to 15 of the periodic table of the elements, and
wherein the doped silver compound comprises in the range of 50% to 89% silver based on total solids weight of the doped silver compound.
US Pat. No. 10,918,677

ATTENUATED OR INACTIVATED PATHOGENIC ESCHERICHIA COLI FOR TREATING UROGENITAL CANCER

YISSUM RESEARCH DEVELOPME...

1. A method of treating bladder cancer, the method comprising using a catheter for intravesicularly administering to a subject in need thereof an inactivated pathogenic E. coli strain.
US Pat. No. 10,919,189

BIOCOMPOSITE AND/OR BIOMATERIAL WITH SUNFLOWER SEED SHELLS/HUSKS

SPC SUNFLOWER PLASTIC COM...

1. A process for the production of a sunflower-based composite material, comprising:separating sunflower seed husks from sunflower seed cores by a peeling process;
processing the separated sunflower seed husks so that:
the water content of the sunflower seed husks is reduced to no more than 15% of the mass of the sunflower seed husks;
the sunflower seed husks are comminuted or ground to a desired grain size; and
the fat content of the sunflower seed husks is reduced by subjecting the sunflower seed husks to a fat absorption process; and
compounding the processed sunflower seed husks with a plastics material to produce the sunflower-based composite material;
wherein the fat content of the sunflower seed husks is reduced to no more than 6% of the mass of the sunflower seed husks.
US Pat. No. 10,919,958

ANTI-VEGF-A ANTIBODIES AND USES THEREOF

MEDIMMUNE LIMITED, Cambr...

1. A antibody comprising heavy chain complementarity determining regions 1-3(HCDR1, HCDR2, and HCDR3) and light chain complementarity determining regions 1-3 (LCDR1, LCDR2, and LCDR3), wherein HCDR1, HCDR2, and HCDR3 and LCDR1, LCDR2, and LCDR3 comprise SEQ ID NOs: 79-84, respectively.
US Pat. No. 10,920,214

MICROBIAL FERMENTATION METHODS AND COMPOSITIONS

NEWLEAF SYMBIOTICS, INC.,...

1. A method for obtaining a Methylobacterium preparation comprising:(i) inoculating a monoculture of a Methylobacterium strain into media that comprises a liquid phase and a solid phase to an initial titer of at least 1×105 colony-forming units per milliliter of the Methylobacterium in the media, wherein the liquid and solid phase were sterile prior to inoculation of the Methylobacterium strain, wherein said solid phase comprises a plurality of particles which are suspended in the liquid phase, wherein the particles are about 1 micron to about 1000 microns in average length and diameter, wherein the particles provide for increased yield of said Methylobacterium relative to yield obtained by growing the Methylobacterium in liquid media alone, wherein said solid substance is not a viable photosynthetic microorganism, and wherein the monoculture is essentially free of contaminating microorganisms;
(ii) growing the monoculture of a Methylobacterium strain in the media that comprises a liquid phase and a solid phase to provide a fermentation broth, wherein the Methylobacterium titer in the fermentation broth is increased at least 1,000-fold from the initial titer of Methylobacterium in the inoculated media of step (i); and
(iii) harvesting the Methylobacterium strain grown in the media, thereby obtaining the Methylobacterium preparation.
US Pat. No. 10,918,678

FAECALIBACTERIUM PRAUSNITZII STRAIN CNCM 1-4573 FOR THE TREATMENT AND PREVENTION OF GASTROINTESTINAL INFLAMMATION

INSTITUT NATIONAL DE LA R...

1. Method for the treatment of an inflammatory gastrointestinal disease in an individual comprising administering to the said individual a bacterial strain of the species Faecalibacterium prausnitzii deposited with the CNCM under accession number CNCM 1-4573.
US Pat. No. 10,919,959

ANGPTL3/8 COMPLEXES AND METHODS OF USING THE SAME

Eli Lilly and Company, I...

2. An angiopoietin-like peptide (ANGPTL)3/8 complex comprising a polypeptide having an amino acid sequence of SEQ ID NO:19 and a polypeptide having an amino acid sequence of SEQ ID NO:20.
US Pat. No. 10,920,215

METHOD FOR MODIFYING GENOME SEQUENCE TO INTRODUCE SPECIFIC MUTATION TO TARGETED DNA SEQUENCE BY BASE-REMOVAL REACTION, AND MOLECULAR COMPLEX USED THEREIN

National University Corpo...

1. A method of modifying a targeted site of a double stranded DNA in a eukaryotic cell, comprisingcontacting a complex with the double stranded DNA, wherein the complex comprises a nucleic acid sequence-recognizing module and a mutant of uracil DNA glycosylase having reduced reactivity with unrelaxed DNA to avoid cytotoxicity,
wherein the nucleic acid sequence-recognizing module specifically binds to a target nucleotide sequence in the targeted site of the double stranded DNA,
wherein the mutant of uracil DNA glycosylase is
(i-a) a mutant of yeast UNG1 having N222D/L304A mutations, N222D/R308E mutations, N222D/R308C mutations, Y164A/L304A mutations, Y164A/R308E mutations, Y164A/R308C mutations, Y164G/L304A mutations, Y164G/R308E mutations, Y164G/R308C mutations, N222D/Y164A/L304A mutations, N222D/Y164A/R308E mutations, N222D/Y164A/R308C mutations, N222D/Y164G/L304A mutations, N222D/Y164G/R308E mutations or N222D/Y164G/R308C mutations, or
(i-b) a mutant of Uracil DNA Glycosylase (UNG) other than a mutant of (i-a) and having mutations corresponding to the mutations of the mutant of (i-a),
thereby converting one or more nucleotides in the targeted site to other one or more nucleotides or deleting one or more nucleotides, or inserting one or more nucleotides into said targeted site, without a double stranded DNA break in the targeted site.
US Pat. No. 10,918,679

COMPOSITIONS AND METHODS FOR REDUCING BLOOD ALCOHOL CONTENT

LIFE WELL LIVED, LLC, Au...

1. A composition comprising 25-100 billion cfu of Lactobacillus, 25-100 billion cfu of Bifidobacterium, 5-15 mg of NAD+, vitamin E, and a vitamin B.
US Pat. No. 10,919,960

METHOD OF USING ANTI-APRIL (A PROLIFERATION-INDUCING LIGAND) ANTIBODIES TO REDUCE IGA

VISTERRA, INC., Waltham,...

1. A method of reducing the level of IgA in a cell or subject, the method comprising contacting the cell or subject with an anti-A PRoliferation-Inducing Ligand (APRIL) antibody molecule,wherein the antibody molecule comprises a heavy chain variable region (VH) comprising three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) and a light chain variable region (VL) comprising three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3),
wherein the VH comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 11; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 12, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 13; and the VL comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 280; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 285, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16; or
wherein the VH comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 17; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 282, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 13; and the VL comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 280; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 285, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 16,
thereby reducing the level of IgA.
US Pat. No. 10,919,961

METHODS AND COMPOSITIONS FOR TREATING ASTHMA USING ANTI-IL-13 ANTIBODIES

Abbvie, Inc., North Chic...

1. A method of treating mild to moderate asthma in a human subject comprising subcutaneously administering to the human subject an anti-IL-13 antibody, or antigen-binding portion thereof, comprising a heavy chain variable region as set forth in SEQ ID NO:2 and a light chain variable region as set forth in SEQ ID NO:3 at a dose of about 0.3 mg/kg, wherein(a) a half-life of between about 24 and 31 days;
(b) a Tmax of between about 3 and about 5 days;
(c) a bioavailability of at least about 60%,
(d) a clearance rate of between about 0.08 to about 0.14 mL/hr/kg; and
(e) a volume of distribution of between about 55 to about 100 mL/kg,is achieved following administration of the antibody, or antigen-binding portion thereof to said human subject.
US Pat. No. 10,920,217

DE NOVO DESIGN OF ALLOSTERIC PROTEINS

President and Fellows of ...

1. A method of making an allosteric DNA binding protein that binds to a companion allosteric effector which induces a conformation change comprising:introducing a nucleic acid sequence encoding a candidate allosteric DNA binding protein having a binding pocket for the companion allosteric effector into a cell and expressing the candidate allosteric DNA binding protein, wherein the candidate allosteric DNA binding protein is designed computationally in silico, and derived from a single natural polypeptide, and
determining whether the candidate allosteric DNA binding protein binds to DNA and inhibits expression of a gene by:
(i) using negative selection to identify a first plurality of cells where the candidate allosteric DNA binding protein has bound to DNA and inhibited expression of the gene, and
(ii) using positive selection to identify a second plurality of cells where the candidate allosteric DNA binding protein has bound to the companion allosteric effector.
US Pat. No. 10,918,681

METHOD FOR REGULATING EXPRESSION OF PDGFC, FGF2, IGF1R, PTGIS, NOS3, EDN1, PLAT, PROC, VWF, F3, SERPINE1, IL-8, ICAM1, VCAM1, AND CASP8 GENES

TCI CO., LTD., Taipei (T...

1. A method of treating thrombosis in a human in need thereof consisting essentially of administering to the human in need thereof therapeutically effective amounts of an extract selected from the group consisting of Pu-erh extract and four seasons spring tea extract and an extract selected from the group consisting of spinach extract, black tea extract, grape seed extract, and red wine extract to effectively treat the thrombosis in the human in need thereof.
US Pat. No. 10,919,962

METHOD OF REDUCING TUMOR GROWTH WITH IL-1BETA NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES

Agency for Science, Techn...

1. A method of reducing tumor growth in a subject in need thereof, comprising administering to the subject an effective amount of an isolated monoclonal antibody, which specifically binds to IL-1?, or an antigen binding fragment thereof, wherein said antibody or fragment thereof comprises:(i) Complementarity Determining Regions (CDRs) according to the Kabat numbering convention of a light chain comprising the amino acid sequence of SEQ ID NO: 17; and
(ii) CDRs according to the Kabat numbering convention of a heavy chain comprising the amino acid sequence of SEQ ID NO: 14.
US Pat. No. 10,920,218

HIGH THROUGHPUT DISCOVERY OF NEW GENES FROM COMPLEX MIXTURES OF ENVIRONMENTAL MICROBES

AgBiome, Inc., Durham, N...

1. A method for identifying a variant of a gene of interest having less than 95% identity to said gene of interest, in a complex sample, said method comprising:a) preparing DNA from a complex sample comprising a variant of a gene of interest for hybridization thereby forming a prepared sample DNA, the prepared sample DNA comprising said variant of said gene of interest, wherein said gene of interest comprises an insecticidal gene;
b) mixing said prepared sample DNA with a labeled bait pool comprising polynucleotide sequences complementary to said insecticidal gene of interest;
c) hybridizing the prepared sample DNA to said labeled bait pool under conditions that allow for hybridization of a labeled bait in said labeled bait pool with said variant of said insecticidal gene of interest to form one or more hybridization complexes,
wherein said variant of said insecticidal gene of interest in the hybridization complexes comprises captured DNA;
d) sequencing said captured DNA to determine a sequence read of said variant of said insecticidal gene of interest; and
e) aligning said sequence read to a database of known sequences using a sequence alignment program in order to identify said variant of said insecticidal gene of interest having less than 95% identity to said insecticidal gene of interest.
US Pat. No. 10,918,682

METHOD OF ENHANCING THE GENE EXPRESSION LEVEL OF TGM1, KRT, AQP3, FLG, GBA, AND HAS USING PLANT EXTRACTS

TCI CO., LTD., Taipei (T...

1. A method of treating human skin in need of moisturization in a human in need thereof consisting essentially of administering to the human in need thereof therapeutically effective amounts of an extract selected from the group consisting of Pu-erh extract and Four seasons spring tea extract, and an extract selected from the group consisting of spinach extract and blueberry extract.
US Pat. No. 10,919,963

ERYTHROCYTE-BINDING THERAPEUTICS

1. A composition for use in inducing tolerance comprising:an antigen to which tolerance is desired;
wherein the antigen is selected from an immunogenic portion of myelin oligodendrocyte glycoprotein, myelin oligodendrocyte glycoprotein, and combinations thereof;
an erythrocyte-binding moiety,
wherein the erythrocyte-binding moiety has the ability to non-covalently, specifically bind an exterior erythrocyte surface in situ in blood,
wherein the erythrocyte-binding moiety comprises an antibody fragment directed against glycophorin A,
wherein the antigen to which tolerance is desired is recombinantly fused to the erythrocyte-binding moiety,
wherein, upon administration to a human in which tolerance to the antigen is desired:
the composition binds to CD45 negative cells, but not to CD45 positive cells, and the composition reduces, fails to induce, or prevents inflammatory responses in antigen-specific T cells as compared to when the human is exposed to the antigen alone.
US Pat. No. 10,918,683

METHODS TO REDUCE FAT ACCUMULATION AND OXIDATIVE DAMAGE IN LIVER USING GREEN MANGO EXTRACTS AND COMPOUNDS OBTAINED THEREFROM

TCI CO., LTD., Taipei (T...

1. A method for reducing fat accumulation and oxidative damage to a liver cell, comprising the step of contacting the liver cell with a composition comprising an effective amount of an early-harvested mango extract, wherein the early-harvested mango extract is obtained by extraction of an early-harvested mango with a solvent; the early-harvested mango is a mango fruit that has not entered its maturation period; and the effective amount is at least 1 mg/mL.
US Pat. No. 10,919,964

ANTIGEN BINDING PROTEINS THAT BIND PD-L1

Sorrento Therapeutics, In...

1. A fully human antibody of an IgG class that binds to human PD-L1, wherein the antibody comprises a heavy chain variable domain comprising a CDR1 domain, a CDR2 domain, and a CDR3 domain as set forth in the amino acid sequences of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, respectively, and comprises a light chain variable domain comprising an amino acid sequence as set forth in SEQ ID NO. 2 and wherein the antibody is an IgG1 or an IgG4 antibody.
US Pat. No. 10,920,220

METHODS FOR DETERMINING RECOMBINATION DIVERSITY AT A GENOMIC LOCUS

Icahn School of Medicine ...

1. A universal primer based method for determining recombination diversity at a genomic locus of interest in a subject, the method comprising:a) isolating nucleic acids from a biological sample containing immune cells from the subject;
b) fragmenting the isolated nucleic acids, thereby forming a plurality of fragmented nucleic acids, wherein the plurality of fragmented nucleic acids contains a sub-plurality of at least 10 fragmented nucleic acids having a recombined junction and a constant region from the genomic locus of interest, wherein the fragments are at least 100 bp;
c) ligating first adaptor nucleic acids to the ends of respective nucleic acids corresponding to the plurality of fragmented nucleic acids, the first adaptor nucleic acids comprising a first hybridization region having a first predefined hybridization sequence, thereby forming a plurality of ligated nucleic acid fragments;
d) selectively amplifying respective ligated nucleic acid fragments, in the plurality of ligated nucleic acid fragments, containing the recombined junction using only universal primers:
when the recombined junction is 5? to the constant region:
i) a first universal primer that hybridizes, at the first hybridization region, to the Crick strand of respective ligated nucleic acid fragments in the plurality of ligated nucleic acid fragments; and
ii) a second universal primer that hybridizes, at a first site in the constant region 3? to the recombined junction at the genomic locus of interest, to the Watson strand of respective ligated nucleic acids containing the recombined junction at the genomic locus of interest in the plurality of ligated nucleic acid fragments, or
when the recombined junction is 3? to the constant region:
i) a first universal primer that hybridizes, at the first hybridization region, to the Watson strand of respective ligated nucleic acid fragments in the plurality of ligated nucleic acid fragments; and
ii) a second universal primer that hybridizes, at a first site in the constant region 5? to the recombined junction at the genomic locus of interest, to the Crick strand of respective ligated nucleic acids containing the recombined junction at the genomic locus of interest in the plurality of ligated nucleic acid fragments,
thereby forming a plurality of amplified nucleic acid fragments, from the sub-plurality of at least 10 fragmented nucleic acids, having recombined junctions at the genomic locus of interest, wherein >90% of the amplified nucleic acid fragments comprise CDR3 sequences; and
e) sequencing amplified nucleic acid fragments in the plurality of amplified nucleic acid fragments,
wherein the genomic locus of interest is selected from the group consisting of a T cell receptor ?-locus, a T cell receptor ?-locus, a T cell receptor ?-locus, a T cell receptor ?-locus, a B cell receptor ?-heavy chain locus, a B cell receptor ?-light chain locus, a B cell receptor ?-heavy chain locus, a B cell receptor ?-light chain locus, a B cell receptor ?-heavy chain locus, and a B cell receptor ?-light chain locus.
US Pat. No. 10,918,684

VAPORIZED MEDICANTS AND METHODS OF USE

CQENS TECHNOLOGIES, INC.,...

1. A method for delivering medicants through inhalation, comprising:a. acquiring a medicant solution suitable for vaporization, the medicant solution, comprising:
i. an excipient comprising propylene glycol present at approximately 1 percent to approximately 30 percent of the excipient, vegetable glycerin present at approximately 1 percent to approximately 30 percent of the excipient, water present at approximately 0.01 percent to approximately 30 percent of the excipient, and alcohol present at approximately 0.01 percent to approximately 30 percent of the excipient, and
ii. phosphodiesterase type 5 inhibitor; and
b. vaporizing the medicant solution at a temperature ranging from approximately 90 degrees C. to approximately 385 degrees C. such that an effective serving of the medicant solution is provided to a user for inhalation, wherein the step of vaporizing the medicant solution comprises using a vaporizer.
US Pat. No. 10,919,965

COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE

BRISTOL-MYERS SQUIBB COMP...

1. A domain antibody (dAb) comprising an amino acid sequence that differs from that of SEQ ID NO:272, SEQ ID NO:273, SEQ ID NO:276, SEQ ID NO: 599, SEQ ID NO: 600, SEQ ID NO: 607, SEQ ID NO: 611, SEQ ID NO: 617, or SEQ ID NO: 622 by no more than 10 amino acids, wherein the dAb binds to CD28.
US Pat. No. 10,920,221

METHODS OF MAKING AND USING GUIDE RNA FOR USE WITH CAS9 SYSTEMS

President and Fellows of ...

1. A method of delivering a selected RNA sequence to a target nucleic acid in a cell comprisingproviding to the cell a Cas9 protein wherein the Cas9 protein is provided to the cell by introducing into the cell a first foreign nucleic acid encoding the Cas9 protein and
providing to the cell a guide RNA wherein the guide RNA is provided to the cell by introducing into the cell a second foreign nucleic acid encoding the guide RNA and a Pol II promoter sequence and a Pol II terminator sequence, wherein the Pol II promoter sequence is CMVPro or U1Pro and the Pol II terminator sequence is U1 3?Box, MASC or U2 smBox/U1 3?Box, wherein the guide RNA includes a spacer sequence and a tracr mate sequence forming a crRNA and a tracr sequence and has a selected RNA domain attached to the guide RNA,
wherein the guide RNA and the Cas9 protein are expressed, and
wherein the guide RNA and the Cas9 protein form a co-localization complex with the target nucleic acid to deliver the selected RNA sequence to the target nucleic acid.
US Pat. No. 10,918,685

HERBAL TOPICAL COMPOSITION FOR MUSCLE AND JOINT HEALTH, RECOVERY FROM EXERTION, AND FOR PAIN MANAGEMENT

1. A topical composition to boost muscle relaxation, increase blood flow, and increase cutaneous delivery of herbal extract that contains polyphenols comprises:a quantity of castor-mineral oil-camphor solution;
a quantity of eucalyptus oil;
a quantity of clove oil;
a quantity of peppermint oil;
a quantity of frankincense oil;
a quantity of herbal extract concentrate solution;
a quantity of castor oil; and
the quantity of castor-mineral oil-camphor solution, the quantity of eucalyptus oil, the quantity of clove oil, the quantity of peppermint oil, the quantity of frankincense oil, the quantity of herbal extract concentrate solution, and the quantity of castor oil being heterogeneously mixed into a topical liniment composition.
US Pat. No. 10,919,966

ANTIBODY TO PROGRAMMED DEATH-LIGAND 1 (PD-L1) AND USE THEREOF

Y-BIOLOGICS INC., Daejeo...

1. An antibody binding to PD-L1 or an antigen-binding fragment thereof, comprising:a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 1, the heavy chain CDR2 of SEQ ID NO: 8 and the heavy chain CDR3 of SEQ ID NO: 16, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 88, the light chain CDR2 of SEQ ID NO: 103 and the light chain CDR3 of SEQ ID NO: 120;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 121;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 18, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 90, the light chain CDR2 of SEQ ID NO: 105 and the light chain CDR3 of SEQ ID NO: 122;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 3, the heavy chain CDR2 of SEQ ID NO: 10 and the heavy chain CDR3 of SEQ ID NO: 19, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 91, the light chain CDR2 of SEQ ID NO: 106 and the light chain CDR3 of SEQ ID NO: 123;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 4, the heavy chain CDR2 of SEQ ID NO: 11 and the heavy chain CDR3 of SEQ ID NO: 20, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 107 and the light chain CDR3 of SEQ ID NO: 124;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 5, the heavy chain CDR2 of SEQ ID NO: 12 and the heavy chain CDR3 of SEQ ID NO: 21, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 92, the light chain CDR2 of SEQ ID NO: 108 and the light chain CDR3 of SEQ ID NO: 122;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 6, the heavy chain CDR2 of SEQ ID NO: 13 and the heavy chain CDR3 of SEQ ID NO: 22, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 93, the light chain CDR2 of SEQ ID NO: 109 and the light chain CDR3 of SEQ ID NO: 125;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 23, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 94, the light chain CDR2 of SEQ ID NO: 110 and the light chain CDR3 of SEQ ID NO: 126;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 7, the heavy chain CDR2 of SEQ ID NO: 14 and the heavy chain CDR3 of SEQ ID NO: 24, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 95, the light chain CDR2 of SEQ ID NO: 111 and the light chain CDR3 of SEQ ID NO: 127;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 15 and the heavy chain CDR3 of SEQ ID NO: 25, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 96, the light chain CDR2 of SEQ ID NO: 112 and the light chain CDR3 of SEQ ID NO: 128;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 108 and the light chain CDR3 of SEQ ID NO: 129;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 105 and the light chain CDR3 of SEQ ID NO: 130;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 113 and the light chain CDR3 of SEQ ID NO: 131;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 97, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 132;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 133;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 97, the light chain CDR2 of SEQ ID NO: 114 and the light chain CDR3 of SEQ ID NO: 134;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 92, the light chain CDR2 of SEQ ID NO: 115 and the light chain CDR3 of SEQ ID NO: 135;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 98, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 130;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 116 and the light chain CDR3 of SEQ ID NO: 121;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 108 and the light chain CDR3 of SEQ ID NO: 136;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 99, the light chain CDR2 of SEQ ID NO: 105 and the light chain CDR3 of SEQ ID NO: 137;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 117 and the light chain CDR3 of SEQ ID NO: 138;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 118 and the light chain CDR3 of SEQ ID NO: 133;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 119 and the light chain CDR3 of SEQ ID NO: 139;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 100, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 140;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 108 and the light chain CDR3 of SEQ ID NO: 141;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 105 and the light chain CDR3 of SEQ ID NO: 139;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 142;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 89, the light chain CDR2 of SEQ ID NO: 105 and the light chain CDR3 of SEQ ID NO: 143;
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 101, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 141; or
a heavy chain variable region comprising the heavy chain CDR1 of SEQ ID NO: 2, the heavy chain CDR2 of SEQ ID NO: 9 and the heavy chain CDR3 of SEQ ID NO: 17, a light chain variable region comprising the light chain CDR1 of SEQ ID NO: 102, the light chain CDR2 of SEQ ID NO: 104 and the light chain CDR3 of SEQ ID NO: 144.
US Pat. No. 10,920,222

TREATING AND PREVENTING MICROBIAL INFECTIONS

1. A method of treating or reducing an infection that is associated with septicemia and is caused by first bacteria in a subject, the method comprising selectively killing the first bacteria comprised by the subject by cutting a target site comprised by the genomes of the first bacteria, wherein the cutting is carried out using a Cas nuclease that is programmed by a guide RNA to cut the target site, wherein the first bacteria are Enterobacteriaceae bacteria selected from the group consisting of Escherichia, Salmonella, Klebsiella, Shigella, Enterobacter and Citrobacter, wherein the subject comprises second bacteria of one or more strains or species that are different from that of the first bacteria, wherein the genomes of the second bacteria do not comprise the target site, wherein the genomes of the second bacteria are not cut by the Cas nuclease in the subject, whereby second bacteria survive in the presence of the Cas nuclease in the subject.
US Pat. No. 10,918,686

OLEO GEL COMPOSITION AND DELIVERY SYSTEM WITH ACTIVE COMPOUNDS FROM CANNABIS SATIVA AND MENTHA ARVENSIS FOR REDUCTION OF INFLAMMATION AND PAIN IN DEEP TISSUES

UAB Satimed, Vilnius (LT...

1. A topical composition for the treatment and/or reduction of deep tissue joint and muscle inflammation resulted from mechanical trauma of skeletal muscles or arthritis/osteoarthritis (OA), the topical composition comprising:82% olive oil;
about 8.2% silica colloidal anhydrous;
about 0.5% mint oil; and
12% Cannabis sativa extract,
wherein the Cannabis sativa extract contains Cannabidiol (CBD), Cannabidiolic acid (CBDA), Cannabivarin (CBV), and Cannabigerol (CB-G) in an amount equal to 2% of a total mass of cannabis extract, the phytocannabinoids being introduced with a ratio of CBDA and CBD 1:1, 1%:1%, respectively.
US Pat. No. 10,919,198

PRODUCTION OF COMPLEX HOLLOW FOAM OR SANDWICH STRUCTURES BY MEANS OF A MOLD CORE

Evonik Operations GmbH, ...

1. A process for producing at least one complex rigid foam core, the process comprising:producing a filling core, filled with particles and consisting of a foil,
inserting the filling core into a mold and then closing the mold,
introducing matrix particles into a cavity between the filling core and an inside wall of the mold,
foaming the matrix particles, opening the mold, and withdrawing a rigid foam core,
optionally opening the foil at an accessible former contact region from the inserting, and
withdrawing the particles from the rigid foam core,
wherein the matrix particles are pre-foamed P(M)I particles having a particle size between 1.0 and 25.0 mm or are P(M)I suspension polymers having a particle size between 0.1 and 1.0 mm.
US Pat. No. 10,919,967

ANTIBODIES AGAINST MAC-1

1. An isolated monoclonal antibody or an antigen-binding portion thereof whicha) binds to Mac-1,
b) specifically inhibits the interaction of CD40L with activated Mac-1,
c) does not bind to non-activated Mac-1, and
d) does not induce integrin outside-in signaling,characterized in that it binds specifically to a peptide having the sequence SEQ ID NO: 9 and that it comprises six CDRs selected from the group consisting of SEQ ID NOs:2-4 and SEQ ID NOs:6-8.
US Pat. No. 10,920,223

SERPINA1 IRNA COMPOSITIONS AND METHODS OF USE THEREOF

Alnylam Pharmaceuticals, ...

1. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of a serine peptidase inhibitor, clade A member 1 (Serpina1) in a cell, wherein said dsRNA agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein the antisense strand comprises at least 19 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of 5?-UUUUGUUCAAUCAUUAAGAAGAC-3? (SEQ ID NO: 419),wherein the sense strand and the antisense strand are each independently 19-25 nucleotides in length,
wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, and
wherein at least one strand is conjugated to a ligand through a bivalent or trivalent branched linker.
US Pat. No. 10,919,968

FRIZZLED5 PROTEIN-BINDING AGENTS

MODMAB THERAPEUTICS CORPO...

1. An isolated FZD5-binding agent that binds FZD5 with an affinity (KD) less than or equal to 200 picomolar, comprising an antibody variable region that specifically binds human FZD5 and wherein the antibody variable region comprises the complementarity determining regions (CDRs) of an antibody variable region selected from antibody variable region IDs Fv-2898 to Fv-2936, wherein the amino acid sequences of the CDRs for each antibody variable region are shown in Tables 3A-C and Tables 4A-C.
US Pat. No. 10,920,224

PROTECTING RNAS FROM DEGRADATION USING ENGINEERED VIRAL RNAS

The Regents of the Univer...

1. A synthetic ribonucleic acid (RNA) duplex comprising a first exonuclease resistant RNA sequence hybridized to a second heterologous RNA sequence, wherein a region of said first exonuclease resistant RNA sequence and a region of said second heterologous RNA sequence comprise an, interwoven pseudoknot structure, and wherein the first exonuclease resistant RNA sequence comprises nucleotides 10-60 of SEQ ID NO:2.
US Pat. No. 10,918,688

PHYTOCHEMICAL ENHANCED WATER

1. A method of preparing phytochemical-fortified water or beverage, comprising the steps:(a) placing live, fresh cuttings of aerial or leafy sections of Bacopa, Centella, or a combination thereof into water, wherein the water has at least trace amounts of minerals;
wherein the trace amounts of minerals are at least sodium, calcium, and potassium;
wherein the water has a pH of 7 to 7.8 or greater;
(b) maintaining the live, fresh cutting of aerial or leaf leafy sections of Bacopa, Centella, or a combination thereof in the water in a live state for at least two weeks: and
(c) extracting phytochemicals from the fresh cuttings of aerial or leafy sections of Bacopa, Centella, or a combination thereof into the water, wherein the extracting step is at between 1.6° C. and 10° C. for the at least 2 weeks of the maintaining step;
wherein the extracting step forms the phytochemical-fortified water or beverage.
US Pat. No. 10,920,225

ANTISENSE OLIGONUCLEOTIDE FOR SPLICING ADJUSTMENT OF MUTANT DOPA DECARBOXYLASE GENE AND USING METHOD THEREOF

TAICHUNG VETERANS GENERAL...

1. A synthetic single stranded antisense oligonucleotide comprising at least one chemically modified phosphodiester bond for splicing adjustment of mutant dopa decarboxylase gene which is 84% to 100% complementary to nucleotides 1-101 or nucleotides 319-369 of SEQ ID NO: 1,wherein the sequence of the oligonucleotide is selected from one of SEQ ID NOs: 2, 3, 4, 5, or 6.
US Pat. No. 10,918,689

SOLID BEVERAGE FOR CONDITIONING ALLERGIC CONSTITUTION AND METHOD FOR PRODUCING THE SAME

1. A solid beverage, comprising the following components in parts by weight: 18-45 parts of smoked plum, 10-30 parts of perilla, 18-45 parts of lilium brownii, 10-30 parts of purslane, 10-30 parts of coix seed, 10-30 parts of semen hoveniae, 7-20 parts of dahurian angelica, 15-40 parts of dextrin, 9-23 parts of maltodextrin, 9-23 parts of soluble starch and 0.1-0.3 parts of aspartame.
US Pat. No. 10,919,970

ANTI-EPHA4 ANTIBODY

1. An anti-EphA4 antibody, whereinthe anti-EphA4 antibody comprises heavy and light chains, and comprises:
(a) a heavy chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO. 44;
(b) a heavy chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO. 27;
(c) a heavy chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO. 28;
(d) a light chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO. 29;
(e) a light chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO. 30; and
(f) a light chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO. 31.
US Pat. No. 10,920,226

SIRNA TARGETING LDHA

Thermo Fisher Scientific ...

1. A siRNA molecule comprising a sense strand and an antisense strand forming a duplex region of 18 to 30 base pairs in length, wherein the siRNA molecule targets a LDHA (lactate dehydrogenase A) gene with the sequence of GenBank Accession NM_005566.1 and the siRNA molecule comprisesa low GC content, between 30% and 53%; and
a U base at position 10 of the sense strand; and
a base other than C at position 19 of the sense strand; and
a base other than G at position 13 of the sense strand.
US Pat. No. 10,919,971

PRION PROTEIN ANTIBODIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE

D-GEN LIMITED, London (G...

1. A method of treating Alzheimer's Disease in a subject, the method comprising administering to the subject a therapeutically effective amount of an anti-prion protein (anti-PrP) antibody having the complementarity determining sequences (CDRs) DYNLD (amino acids 50 to 54 of SEQ ID NO:4), NVYPNNGVTGYNQKFRG (amino acids 69 to 85 of SEQ ID NO:4), YYYDVSY(amino acids 118 to 124 of SEQ ID NO:4), SASSSVSYMH (amino acids 46 to 55 of SEQ ID NO:6), DTSKLAS (amino acids 71 to 77 of SEQ ID NO:6), and HQWRSNPYT (amino acids 110 to 118 of SEQ ID NO:6).
US Pat. No. 10,920,227

COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)

VOYAGER THERAPEUTICS, INC...

1. An adeno-associated virus (AAV) vector genome comprising a nucleic acid sequence positioned between two inverted terminal repeats (ITRs); wherein said nucleic acid sequence encodes a sense strand sequence and an antisense strand sequence of an siRNA duplex; wherein the antisense strand sequence comprises nucleotides 1-17 of SEQ ID NO. 292; and wherein the sense strand sequence comprises nucleotides 1-19 of SEQ ID NO. 123 or nucleotides 1-19 of SEQ ID NO. 124.
US Pat. No. 10,918,691

MODULATORS OF COMPLEMENT ACTIVITY

RA PHARMACEUTICALS, INC.,...

1. A method of reducing hemolysis in a subject, the method comprising administering a C5 inhibitor to the subject, wherein the C5 inhibitor is administered at a frequency of from about every 12 hours to about every 72 hours, wherein hemolysis in subject plasma is reduced by at least 90% during the course of administration, and wherein the C5 inhibitor comprises a polypeptide comprising the formula R1-Tbg-Tyr-Xaa0-Glu-R2, wherein:R1 comprises a polypeptide;
Xaa0 is selected from the group consisting of Trp, azaTrp, N-methyl Trp, 1-methyl Trp, and 3-aminomethyl Phe; and
R2 comprises a polypeptide.
US Pat. No. 10,919,972

ANTI-HUMAN 4-1BB ANTIBODIES AND USES THEREOF

Eutilex Co., Ltd., Seoul...

1. A method for treating cancer in a subject in need thereof, comprising:administering to the subject a therapeutically effective amount of activated T cells produced by contacting a population of T cells with an anti-4-1BB antibody or antigen-binding fragment comprising:
(i) a heavy chain CDR1 comprising a sequence of SEQ ID NO: 5, a heavy chain CDR2 comprising a sequence of SEQ ID NO: 6 and a heavy chain CDR3 comprising a sequence of SEQ ID NO: 7 or 8; and
(ii) a light chain CDR1 comprising a sequence of SEQ ID NO: 1, a light chain CDR2 comprising a sequence of SEQ ID NO: 2 and a light chain CDR3 comprising a sequence of SEQ ID NO: 4.
US Pat. No. 10,920,228

FUNCTIONAL LIGANDS TO BIOCIDES

Base Pair Biotechnologies...

1. An artificial ligand binding to benzalkonium chloride comprising a non-naturally occurring nucleic acid sequence of under 40 nucleotides in length having substantial homology and greater than 75% identity to a sequence selected from the group consisting of SEQ ID Nos. 18, 29, 36, 41-42, 48, 71, 82, and 91.
US Pat. No. 10,918,692

USE OF ANTIMICROBIAL PEPTIDES FOR TREATMENT OF CANCER

HUNAN UNIVERSITY OF SCIEN...


US Pat. No. 10,920,229

METHOD FOR IMPROVING HETEROLOGOUS SYNTHESIS OF ESCHERICHIA COLI INTO POLYKETIDES AND USE OF SAME

CAS Center for Excellence...

1. A method for increasing the yield of heterologous synthesis of a polyketide 6-deoxyerythronolide B by 20% or more in an E. coli compared to unattenuated E. coli wherein the method comprises:(1) attenuating an expression of a target gene in the E. coli for synthesizing the polyketide 6-deoxyerythronolide B;
wherein, the target gene is selected from:
(a) a gene for nucleotide synthesis and other metabolism modules: phosphoribosyl glycinamide formyltransferase 2 purT, autoinducer-2ABC transporter lsrC, coproporphyrinogen III dehydrogenase hemN, glucose 6-phosphate-1-dehydrogenase zwf, 6-phosphogluconolactonase pgl, 6-phosphogluconate dehydrogenase gnd, ribulose-5-phosphate 3-epimerase rpe, transaldolase A talA, transaldolase talB, transketolase I tktA, transketolase II tktB, L-xylulose 5-phosphate 3-epimerase ulaE or predicted 6-phosphogluconolactonase yieK;
(b) a gene for pentose phosphate and glyoxylate pathway modules: predicted lyase yaeR, ribose-5-phosphate isomerase A rpiA, allose-6-phosphate isomerase/ribose-5-phosphate isomerase B rpiB, AICAR transformylase purH, aspartate carbamoyltransferase, catalytic subunit pyrB, aspartate carbamoyltransferase, regulatory subunit pyrI, adenosine-3?(2?),5?-bisphosphate nucleotidase cysQ, dihydroorotase pyrC, guanylate kinase gmk, GMP synthetase guaA, IMP dehydrogenase guaB, nucleoside diphosphate kinase ndk, orotidine-5?-phosphate decarboxylase pyrF, orotate phosphoribosyltransferase pyrE, UMP kinase pyrH or hypoxanthine phosphoribosyltransferase hpt;
(c) a gene for TCA cycle and oxidative phosphorylation modules: fumarate reductase frdD, fumarate reductase, a subunit frdA, succinate dehydrogenase A sdhA, succinate dehydrogenase B sdhB, succinate dehydrogenase C sdhC, succinate dehydrogenase D sdhD, succinyl-CoA synthetase, ? subunit sucC, succinyl-CoA synthetase sucD, cytochrome bo terminal oxidase subunit II cyoA or cytochrome bo terminal oxidase subunit I cyoB;
(d) a gene for carbohydrate metabolism module: pyruvate dehydrogenase accF, phosphoglucose isomerase pgi, lipoamide dehydrogenase lpdA, polyphosphate kinase ppk, HPr protein of phosphoenolpyruvate-sugar phosphotransferase system ptsH, PTSI protein of phosphoenolpyruvate-sugar phosphotransferase system ptsI, glycolateoxidase, predicted iron-sulfur subunit glcF, glycolate oxidase, FAD-binding subunit glcE, fructose 6-phosphate aldolase 1 fsaA or N-acetylgalactosameine-specific IIC component 2 of PTS system agaW;
(e) a gene for 6-dEB precursor metabolism module: methylmalonyl-CoA mutase scpA, propionate kinase tdcD, 2-ketobutyrate formatelyase/pyruvate formatelyase 4, inactive tdcE, pyruvate formatelyase pfiB, formate acetyltransferase 2 pfD, predicted 2,3-dehydroadipyl-CoA hydratase PaaF, acetate kinase ackA, phosphate acetyltransferase/phosphate propionyltransferase pta or pyruvate formatelyase ybiW;
(f) a gene for fatty acid metabolism module: FadJ component of anaerobic fatty acid oxidation complex fadJ, fatty acid oxidation complex, a component fadB, dihydroxyacetone kinase subunit K dhaK1, dihydroxyacetone kinase dhaK2 or dihydroxyacetone kinase subunit M dhaH;
(g) a gene for amino acid and protein synthetic metabolism modules: isopropylmalate isomerase leuC, isopropylmalate isomerase lcuD, 3-phosphoserine/phosphohydroxythreonine aminotransferase scrC, phosphoserine phosphatase scrB, D-3-phosphoglycerate dehydrogenase/a-ketoglutarate reductase serA, glutamate dehydrogenase gdhA or tryptophanase/L-cysteine desulhydrase tnaA; or
(h) the combination of frdD+sucC, the combination of IsrC+frdD, the combination of IsrC+sucC, the combination of frdD+rpiA, the combination of talA+guaB or the combination of zwf+guaB; and
(2) culturing the E. coli prepared in step (1), thereby synthesizing the polyketide 6-deoxyerythronolide,
wherein attenuating the expression of the target gene in the E. coli comprises introducing an interfering molecule that inhibits the expression of the target gene or knocking out the target gene,
wherein the interfering molecule that inhibits the expression of the target gene is directed to:a sequence shown in SEQ ID NO: 179 in talB or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 191 in guaB or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 37 in sucC or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 16 in yjiM or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 19 in dhaK2 or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 41 in glcE or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 51 in serC or a full complementary sequence thereof,a sequence shown in SEQ ID NO: 174 in zwf or a full complementary sequence thereof anda sequence shown in SEQ ID NO: 191 in guaB or a full complementary sequence thereof, ora sequence shown in SEQ ID NO: 178 in talA or a full complementary sequence thereof anda sequence shown in SEQ ID NO: 191 in guaB or a full complementary sequence thereof, andwherein the increasing the yield of heterologous synthesis of a polyketide 6-deoxyerythronolide B is being compared to that of unattenuated E. coli.
US Pat. No. 10,918,693

COMPOSITION FOR CELL PROTECTION CONTAINING CYCLO HISTIDINE-PROLINE AS ACTIVE INGREDIENT

NovMetaPharma Co., Ltd., ...

1. A method of treating a subject suffering from a kidney disease,consisting of administering an effective amount of a composition to the subject,
wherein the composition consists of (a) cyclo histidine-proline (CHP) or its pharmaceutically acceptable salt as an active ingredient, and (b) one or more additives selected from the group consisting of sodium starch glycolate, crospovidone, croscarmellose sodium, alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, chitosan, guar gum, low-substituted hydroxypropylcellulose, magnesium aluminum silicate, polacrilin potassium, starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, mannitol, sugar, arabic gum, pregelatinized starch, corn starch, powdered cellulose, hydroxypropylcellulose, opadry, sodium starch glycolate, carnauba lead, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, white sugar, dextrose, sorbitol, and talc,
wherein the administering the composition suppresses apoptosis of kidney cells, and
wherein the kidney disease is selected from the group consisting of chronic pyelonephritis, nephrotic syndrome, nephrogenic diabetes insipidus, and hyperuricemia.
US Pat. No. 10,919,974

ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDIN 6

Ganymed Pharmaceuticals G...

1. A method of producing an antibody, or an antigen binding fragment thereof, that binds to CLDN6, the method comprising the steps of:(a) culturing a human host cell transformed with one or more expression vectors under conditions in which the host cell expresses the antibody or antigen binding fragment thereof; and
(b) harvesting a preparation of the antibody or antigen binding fragment thereof expressed by the human host cell;
wherein the one or more expression vectors comprise:
(i) a nucleic acid sequence encoding a polypeptide comprising the antibody heavy chain CDR1, CDR2, and CDR3 regions having the amino acid sequences of positions 26-33, positions 51-58, and positions 97-106 of SEQ ID NO: 36, respectively; and a nucleic acid sequence encoding a polypeptide comprising the antibody light chain CDR1, CDR2, and CDR3 regions having the amino acid sequences of positions 27-31, positions 49-51, and positions 88-97 of SEQ ID NO: 35, respectively.
US Pat. No. 10,918,694

TOPICAL CYCLOSPORINE-CONTAINING FORMULATIONS AND USES THEREOF

SUN PHARMA GLOBAL FZE, S...

1. An ophthalmic aqueous topical formulation consisting of:0.087-0.093 wt % cyclosporine,
about 1.0 wt % hydrogenated 40 polyoxyl castor oil,
about 0.05 wt % octoxynol-40,
about 0.3 wt % povidone,
about 0.05 wt % sodium chloride,
about 0.20-0.405 wt % sodium phosphate monobasic and about 0.23-0.465 wt % sodium phosphate dibasic, adjusted to a pH of about 5 to about 8 with sodium hydroxide/hydrochloric acid, and
wherein the final volume is made up with water.
US Pat. No. 10,919,206

COTTONSEED OIL BASED LIQUID COLOR COMPOSITION AND PLASTICS COLORING METHOD USING THE SAME

1. A method of fabricating a plastic article of preselected color, comprising:a) preparing a blend comprising: solid plastic resin pellets; a liquid colorant of a hue and in an amount to impart the preselected color to the plastic article to be fabricated, the liquid colorant including cottonseed oil; and a plurality of dispersions each of a single pigment in cottonseed oil; and
b) forming the blend under pressure and heat into the plastic article.
US Pat. No. 10,919,975

ANTI-MESOTHELIN BINDING PROTEINS

AMGEN INC., Thousand Oak...

1. An isolated nucleic acid encoding an antibody, antigen binding protein, or fragment thereof, wherein the antibody, antigen binding protein, or fragment thereof comprises a mesothelin binding domain comprising three heavy chain CDRs and three light chain CDRs with sequences selected from the group consisting of:a) SEQ ID NOs: 45, 46, and 47 of the heavy chain and SEQ ID NOs: 9, 10, and 11 of the light chain;
b) SEQ ID NOs: 48, 49, and 50 of the heavy chain and SEQ ID NOs: 12, 13, and 14 of the light chain;
c) SEQ ID NOs: 51, 52, and 53 of the heavy chain and SEQ ID NOs: 15, 16, and 17 of the light chain;
d) SEQ ID NOs: 51, 52, and 53 of the heavy chain and SEQ ID NOs: 18, 19, and 20 of the light chain;
e) SEQ ID NOs: 54, 55, and 56 of the heavy chain and SEQ ID NOs: 21, 22, and 23 of the light chain;
f) SEQ ID NOs: 57, 58, and 59 of the heavy chain and SEQ ID NOs: 24, 25, and 26 of the light chain;
g) SEQ ID NOs: 60, 61, and 62 of the heavy chain and SEQ ID NOs: 27, 28, and 29 of the light chain;
h) SEQ ID NOs: 63, 64, and 65 of the heavy chain and SEQ ID NOs: 30, 31, and 32 of the light chain;
i) SEQ ID NOs: 63, 64, and 65 of the heavy chain and SEQ ID NOs: 33, 34, and 35 of the light chain;
j) SEQ ID NOs: 63, 64, and 65 of the heavy chain and SEQ ID NOs: 36, 37, and 38 of the light chain, and
k) any one of (a)-(j), wherein each of said CDRs are identical to or comprise 1, 2, or 3 amino acid residue substitutions relative to their specified sequence.
US Pat. No. 10,920,231

SYSTEMS AND METHODS FOR ENHANCING GENE EXPRESSION

The Regents of the Univer...

1. A genetically modified fungal host cell, comprising: (a) a first polynucleotide encoding a fungal transcription factor operably linked to a first promoter that is native to the transcription factor, (b) a second polynucleotide encoding a first biosynthetic enzyme operably linked to a second promoter that is induced or activated by the transcription factor, wherein the first biosynthetic enzyme catalyzes a first reaction which produces a first compound from a second compound, and (c) a third polynucleotide encoding an expression cassette inserted between a polynucleotide encoding a second biosynthetic enzyme and a native promoter of the second biosynthetic enzyme, wherein the expression cassette comprises a polynucleotide encoding the fungal transcription factor, a third promoter that is induced at a level lower than the induction of the first promoter and the second promoter, and a terminator located between the polynucleotide encoding the fungal transcription factor and the third promoter;such that the native promoter of the second biosynthetic enzyme is operatively linked to the polynucleotide encoding the fungal transcription factor, and the third promoter is operatively linked to the polynucleotide encoding the second biosynthetic enzyme; wherein the transcription factor is Upc2, Ecm22, Upc2G888D, or Ecm22G790D and the second biosynthetic enzyme catalyzes a second reaction that is downstream of the first reaction in a metabolic pathway.
US Pat. No. 10,918,695

USE OF JACK BEAN LECTIN FOR INCREASING THE ABUNDANCE OF HEMATOPOIETIC STEM CELLS AND PROGENITOR CELLS IN BONE MARROW AND/OR EPIDERMAL STEM CELLS IN SKIN IN VIVO

THE SECRETARY, DEPARTMENT...

1. A method of treatment of disease condition resulting from deficiency of hematopoietic stem and progenitor cells and/or epidermal stem cells in skin comprising: administering to the subject suffering from said disease condition, an effective amount of Jack bean lectin or a pharmaceutically acceptable salt thereof which is capable of increasing the abundance of hematopoietic stem and progenitor cells and/or epidermal stem cells in skin.
US Pat. No. 10,919,976

IFN-GAMMA-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF

Eutilex Co., Ltd., Seoul...

1. A method of treating a subject with cancer, the method comprising the steps of: administering to the subject a composition that comprises or delivers an IFN-?-Inducible Regulatory T Cell Convertible Anti-Cancer (IRTCA) antibody or antigen-binding fragment thereof, wherein the IRTCA antibody or antigen-binding fragment comprises: (a) a heavy chain CDR1 comprising SEQ ID NO: 8, a heavy chain CDR2 comprising SEQ ID NO: 25, and a heavy chain CDR3 comprising SEC) ID NO: 16, and (b) a light chain CDR1 comprising SEC) ID NO: 11, a light chain CDR2 comprising SEQ ID NO: 12 and a light chain CDR3 comprising of SEQ ID NO: 18.
US Pat. No. 10,920,232

OBTAINING HIGH-PERFORMANCE YEAST STRAINS FOR METABOLIZING ARABINOSE

LESAFFRE et COMPAGNIE, P...

1. A process for obtaining a yeast strain able to metabolize arabinose, glucose, and xylose in the presence of an organic acid in non-dissociated form, comprising:a integrating into the chromosome an L-arabinose isomerase gene (araA), an L-ribulokinase gene (araB) and an L-ribulose-5-P-4 epimerase gene (araD), in a yeast strain able to ferment xylose in the presence of an organic acid in non-dissociated form and having at least one aldose reductase (GRE3) gene inactivated or deleted;
b directly putting the transformed strains into a medium containing arabinose as the sole carbon source, and culturing the strains in the medium for the selection of strains able to metabolize the arabinose, thereby obtaining yeast strains able to metabolize arabinose, glucose, and xylose in the presence of the organic acid;
c optionally selecting transformed strains having metabolized arabinose for their aldose reductase activity less than or equal to 0.002 U/g protein, or even less than or equal to 0.0005 U/g of protein.
US Pat. No. 10,918,696

METHODS OF TREATMENT USING HEMOPEXIN COMPOSITIONS

CSL BEHRING AG, Bern (CH...

1. A method of treating a condition associated with haemolysis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising plasma-derived haptoglobin, wherein said composition further comprises about 0.23% alpha-1-antitrypsin,wherein the percentage of alpha-1-antitrypsin is based on total protein weight and as determined by immune-nephelometry,
wherein the haptoglobin is derived from a Cohn fraction IV precipitate.
US Pat. No. 10,919,977

BISPECIFIC TETRAVALENT ANTIBODIES AND METHODS OF MAKING AND USING THEREOF

SYSTIMMUNE, INC., Bellev...

1. A bispecific tetravalent antibody, said bispecific tetravalent antibody comprising:two IgG1 heavy chains;
two kappa light chains; and
two single chain Fv (scFv) domains;
wherein the two IgG1 heavy chains and kappa light chains form an IgG moiety with a binding specificity to a first member of the EGFR family;
wherein the two scFv domains have a binding specificity to a second member of the EGFR family, and each scFv domain is connected to the C-terminus of either of the IgG1 heavy chains by a connector with an amino acid sequence of (gly-gly-gly-gly-ser)n, to provide a IgG1-connector connection, wherein n is an integral of at least 1;
wherein each scFv domain has a structure order of N terminus—variable heavy chain—linker—variable light chain—C terminus or N-terminus—variable light chain—linker—variable heavy chain—C-terminus, and wherein the linker is comprised of amino acid sequence of (gly-gly-gly-gly-ser)m, wherein m is an integral of at least 3;
wherein at least one of the IgG1 heavy chain, connector, and scFv domain has an amino acid sequence comprising SEQ ID NO 136; and
wherein the kappa light chains comprising an amino acid sequence selected from SEQ ID NO 131 and 132.
US Pat. No. 10,921,257

METHOD AND SYSTEM OF PESTICIDE DETECTION USING SERS

University of Massachuset...

1. A method for mapping one or more analytes contacting a biological structure using surface-enhanced Raman spectroscopy, the method comprising:contacting the biological structure and a metallic nanoparticle;
allowing the metallic nanoparticle to penetrate the biological structure substantially in the z-direction;
collecting a spectrum of the one or more analytes with a Raman spectrometer; and
determining a location of the one or more analytes along a depth in a z-direction and at least one of an x-direction and a y-direction in the biological structure,
wherein a distance between the one or more analytes and an adjacent metallic nanoparticle is in a range of from about 0.10 nm to about 20 nm and determining the location of the one or more analytes along the depth in the z-direction comprises the Raman spectrometer scanning the biological structure at a predetermined depth.
US Pat. No. 10,919,978

ANTIBODY OR ANTIBODY FRAGMENT CAPABLE OF BINDING TO LUNG-SPECIFIC X PROTEIN AND USE THEREOF

IMMUNOPHARMACEUTIC INSTIT...

1. An antibody or antibody fragment capable of binding to a lung-specific X protein, wherein the antibody or antibody fragment comprises heavy chain CDRs with amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 and light chain CDRs with amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6;or the antibody or antibody fragment comprises heavy chain CDRs with amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 7 and SEQ ID NO: 3 and light chain CDRs with amino acid sequences of SEQ ID NO: 8, SEQ ID NO: 5 and SEQ ID NO: 6.
US Pat. No. 10,920,234

METHOD OF PRODUCING TRANSGENIC TARAXACUM PLANT

SUMITOMO RUBBER INDUSTRIE...

1. A method of producing a transgenic Taraxacum plant, comprising:an infection step of infecting a tissue fragment from a Taraxacum plant with an Agrobacterium tumefaciens containing a plasmid containing a target gene or a fragment thereof and a hygromycin-resistance gene;
a selective culture step of selecting the tissue fragment that has acquired the target gene from the tissue fragment obtained in the infection step by using hygromycin;
a callus-inducing step of culturing the tissue fragment obtained in the selective culture step in a callus-inducing medium containing a cytokinin plant hormone, an auxin plant hormone, and a carbon source to form callus;
a regeneration-inducing step of culturing the callus obtained in the callus-inducing step in a regeneration-inducing medium containing a plant growth hormone and a carbon source to form an adventitious embryo, an adventitious bud, and a shoot; and
a rooting step of culturing the shoot obtained in the regeneration-inducing step in a rooting medium to root the shoot,
wherein the selective culture step comprises culturing the tissue fragment obtained in the infection step in a selective culture medium containing 0.1 to 2 mg/L of the hygromycin to select the tissue fragment that has acquired the target gene.
US Pat. No. 10,918,698

LYOPHILIZED PHARMACEUTICAL COMPOSITION OF FC-PEPTIDE FUSION PROTEIN

INTAS PHARMACEUTICALS LTD...

1. A lyophilized pharmaceutical composition comprising Romiplostim, citro-phosphate buffer, Polysorbate 20 as surfactant and bulking agent selected from sucrose, trehalose or a combination thereof.
US Pat. No. 10,919,979

METHODS AND COMPOSITIONS RELATED TO SINGLE CHAIN ANTIBODY FRAGMENTS THAT BIND TO TUMOR-ASSOCIATED GLYCOPROTEIN 72 (TAG-72)

Ohio State Innovation Fou...

1. An antibody fragment which specifically binds tumor-associated glycoprotein 72 (TAG-72), wherein the antibody fragment comprises a sequence having 98% or more identity to SEQ ID NO: 1 or SEQ ID NO: 2, wherein said antibody fragment comprises complementarity determining regions (CDRs), wherein said CDRs comprise amino acid residues 69-85, 101-107, 140-148, 214-218, 233-249, and 282-287 of SEQ ID NOS: 1 or 2.
US Pat. No. 10,920,235

APPARATUS FOR THE PREPARATION AND USE OF PLANT EMBRYO EXPLANTS FOR TRANSFORMATION

Monsanto Technology LLC, ...

1. An apparatus for preparation of transformable embryonic plant tissue from singulated seed comprising:(a) a holder for a singulated seed; and
(b) means for applying a force to the seed being held so as to divide the seed into separate cotyledons, seed coat and embryonic tissue
wherein the holder comprises an upper and lower seed fixture.
US Pat. No. 10,918,699

THERAPEUTIC TREATMENT FOR NEUROTROPHIC KERATOPATHY

1. A method of treating neurotrophic corneal ulcer due to neurotrophic keratopathy or epithelial stem-cell deficiency in a subject in need thereof comprising:contacting the eye of said subject with a neurotrophic corneal ulcer with recombinant human insulin in an ophthalmologically acceptable carrier in amount effective to cause healing of said neurotrophic corneal ulcer, wherein said subject has been diagnosed with neurotrophic keratopathy or epithelial stem-cell deficiency.
US Pat. No. 10,919,980

METHODS OF TREATING TTP WITH IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND USES THEREOF

Ablynx N.V., Ghent-Zwijn...

1. A method of reducing the risk of organ damage by thrombotic thrombocytopenic purpura (TTP) in a human subject in need thereof, comprising:(i) administering to said human subject a dose of 5-40 mg of a polypeptide comprising the amino acid sequence of SEQ ID NO: 1;
(ii) measuring the level of an organ damage marker; and
(iii) repeating step (i) and step (ii) until the level of said organ damage marker is at least 20% of a reference level.
US Pat. No. 10,920,236

USE OF MICROPEPTIDES IN ORDER TO STIMULATE MYCORRHIZAL SYMBIOSIS

CENTRE NATIONAL DE LA REC...

1. A method for promoting mycorrhizal symbiosis between a plant and a fungus, comprising a step of exogenously introducing a miPEP into the plant,said miPEP being naturally present in said plant,
wherein the miPEP (i) is a peptide selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, and SEQ ID NO: 14, (ii) increases the accumulation of an miRNA in said plant relative to a plant that does not comprise exogenously introduced miPEP, and (iii) comprises or consists of an amino acid sequence of the natural miPEP encoded by the primary transcript of said miRNA; and
wherein said miRNA is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, and SEQ ID NO: 13.
US Pat. No. 10,918,700

LIPID-BASED NANOPARTICLES AND USE OF SAME IN OPTIMIZED INSULIN DOSING REGIMENS

SDG, Inc., Cleveland, OH...

1. A method of optimizing the amount of bolus insulin and basal insulin to be administered to a subject having diabetes mellitus or a metabolic derangement, wherein the subject is administered an amount of a bolus insulin HDV composition comprising a lipid-based nanoparticle, wherein the bolus insulin is dispersed within the nanoparticle, wherein the subject is further administered an amount of basal insulin,the method comprising varying the administered amount of the bolus insulin HDV composition and the administered amount of the basal insulin so as to identify the optimized amount of the bolus insulin HDV composition and the optimized amount of the basal insulin to be administered to the subject to afford therapeutically effective blood glucose control without significant hypoglycemia;
wherein the insulin ratio between the optimized administered bolus insulin HDV composition and the optimized administered basal insulin is equal to or lower than 1:1 when the subject has >8.5% HbA1c, and is equal to or higher than 1:1 when the subject has <8.5% HbA1c;
wherein the subject does not experience significant iatrogenic hyperinsulinemia;
wherein the nanoparticle is enclosed by a bipolar lipid membrane comprising cholesterol, dicetyl phosphate, an amphipathic lipid, and a hepatocyte receptor binding molecule;
wherein the amphipathic lipid comprises at least one selected from the group consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycerol-[3-phospho-rac-(1-glycerol)], 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(succinyl), 1,2-dimyristoyl-sn-glycero-3-phosphate, 1,2-dimyristoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphate, 1,2-dipalmitoyl-sn-glycero-3-phosphate, and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine;
wherein the at least one hepatocyte receptor binding molecule extends outward from the nanoparticle; and
wherein the size of the nanoparticle ranges from about 10 nm to about 150 nm.
US Pat. No. 10,919,981

AFFINITY PROTEINS AND USES THEREOF

Nectagen, Inc., Kansas C...

1. An affinity scaffold, said affinity scaffold having the following formula:CR1-V-CR2-W-CR3-Z-CR4,
wherein:
said V, W, and Z are each independently not present or comprise one or more amino acids; and
said CR1-CR4 have amino acid sequences that have at least 95% identity to SEQ ID NOs: 2, 4, 6, and 8, respectively;
wherein said affinity scaffold does not comprise the sequence of SEQ ID NO: 1.
US Pat. No. 10,920,237

INCREASE IN MEIOTIC RECOMBINATION IN PLANTS BY INHIBITING AN RECQ4 OR TOP3A PROTEIN OF THE RTR COMPLEX

INSTITUT NATIONAL DE LA R...

1. A process for increasing the frequency of meiotic crossovers in a plant said process comprising:inhibiting in said plant, the expression or the function of:
a protein of the RTR complex known as RECQ4; or
both REQ4A and RECQ4B proteins if said plant belongs to the family of Brassicaceae and expresses two functional RECQ4 proteins, said RECQ4 protein having at least 40% sequence identity with the RECQ4 protein of SEQ ID NO: 1, and comprising a region having at least 60% sequence identity with the region which extends from positions 407 to 959 of the sequence SEQ ID NO:1; and
measuring the frequency of meiotic crossovers in said plant.
US Pat. No. 10,918,701

DELIVERY SYSTEM COMPRISING A PROTEOLYTIC ENZYME OR EFFECTOR THEREOF FOR USE IN A METHOD FOR ORAL TREATMENT AND USES THEREOF

1. A method for reducing fiber tension, fiber volume or both within a fiber of a subject's connective tissue in a subject in need thereof, the method comprising injecting said subject with a composition comprising:a. a physiologically acceptable carrier; and
b. a lipid formulation encapsulating a proteolytic enzyme or an effector thereof, wherein the proteolytic enzyme or effector thereof is at a concentration effective to cause relaxation of said fibers of a connective tissue;
thereby reducing fiber tension, fiber volume or both within said fiber of a subject's connective tissue in a subject in need thereof.
US Pat. No. 10,920,238

WINTER ACONITE FATTY ACID ELONGASE AND USES THEREOF IN THE PRODUCTION OF FATTY ACIDS

National Research Council...

1. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having elongase activity, wherein said polypeptide has at least 95% sequence identity to the full length of the amino acid sequence set forth in SEQ ID NO: 4, and wherein the nucleotide sequence comprises at least one nucleotide substitution, insertion, or non-terminal deletion relative to the nucleotide sequence set forth in SEQ ID NO: 5.
US Pat. No. 10,918,702

THERAPEUTIC ACID CERAMIDASE COMPOSITIONS AND METHODS OF MAKING AND USING THEM

ICAHN SCHOOL OF MEDICINE ...

1. A therapeutic composition comprisinga ceramidase mixture comprising:
an inactive acid ceramidase precursor;
an active acid ceramidase; and
a pharmaceutically acceptable carrier, wherein the composition has no detectable acid sphingomyelinase activity.
US Pat. No. 10,919,983

IMMUNOGLOBULIN VARIABLE REGION CASSETTE EXCHANGE

HUMANIGEN, INC., Burling...

1. A method of engineering an antibody that retains the binding specificity of a reference antibody for a target antigen, the method comprising:(a) obtaining a variable region from the reference antibody;
(b) replacing at least one exchange cassette obtained from a V gene segment, FR1-CDR1-FR2-CDR2-FR3, of the variable region of the reference antibody with a library of corresponding human exchange cassettes from human V-gene segments comprised of immunoglobulin sequences that are germline or a V-gene segment having a human exchange cassette from one human antibody gene, thereby generating a library of hybrid V-regions comprising members in which the at least one exchange cassette of the variable region of the reference antibody is replaced with human corresponding exchange cassettes encoded by different genes, with the proviso that the exchange cassette has less than three framework regions,
wherein the at least one exchange cassette obtained from the V-segment of the variable region of the reference antibody includes at least one intact CDR adjoined to at least one intact FR of the V-segment that are together naturally occurring;
(c) pairing the library of hybrid V regions of (b) with a complementary V-region; and
(d) selecting an antibody comprising a hybrid V region having at least one human exchanged cassette as generated in step (b) that has the binding specificity of the reference antibody and has a reduced potential for immunogenicity in humans,wherein the method is repeated such that alternative exchange cassettes from the antibody comprising a hybrid V region are replaced with human V region cassette sequences as generated in step (b) orwherein the method is carried out iteratively such that the exchange cassettes are serially replaced such that all of the V-gene segment of the reference antibody is replaced by human sequences,(e) replacing a second exchange cassette of the V region of the reference antibody with a library of corresponding exchange cassettes from human V-gene segments comprised of immunoglobulin sequences that are germline or a V-gene segment having a human exchange cassette from a different human antibody gene to create a second hybrid library of hybrid V regions, comprising members in which the second exchange cassette of the variable region of the reference antibody is replaced with human corresponding exchange cassette encoded by a different gene, with the proviso that the exchange cassette has less than three framework regions;
wherein the second exchange cassette obtained from the V-segment of the variable region of the reference antibody comprises at least one intact CDR adjoined to at least one intact FR of the V-segment that are together naturally occurring;
(f) pairing the second library of hybrid V regions with a complementary V-region;
(g) selecting an antibody comprising a hybrid V region having the second human exchanged cassette as generated in step (e), which antibody has a binding affinity for the target antigen; and
(h) combining the at least one human exchanged cassette of the engineered antibody of (d) with the second human exchange cassette of the antibody of (g), to obtain an antibody with the binding specificity of the reference antibody and a higher binding affinity for the target antigen than the reference antibody and having a reduced potential for immunogenicity in humans, wherein the antibody has a hybrid V-region that comprises at least two human exchanged cassettes.
US Pat. No. 10,919,984

POLYMER-BASED RESIN COMPOSITIONS DERIVED FROM CELLULOSE AND ARTICLES MADE USING THESE COMPOSITIONS

Eastman Chemical Company,...

1. An injection molded article comprising a thin-walled body portion formed from a polymer-based resin derived from cellulose,wherein the thin-walled body portion comprises:
i. a gate position;
ii. a last fill position;
iii. a flow length to wall thickness ratio greater than or equal to 100, wherein the flow length is measured from the gate position to the last fill position; and
iv. a wall thickness less than or equal to about 2 mm; and
wherein the polymer-based resin is a cellulose ester composition that comprises an impact modifier in an amount from 1 to 30 wt % and a plasticizer in an amount from 0 to 10 wt %, based on the weight of the cellulose ester composition, and
wherein the polymer-based resin has an HDT or at least 95° C., a bio-derived content of at least 20 wt %, and a spiral flow length of at least 3.0 cm, when the polymer-based resin is molded with a spiral flow mold with the conditions of a barrel temperature of 238° C., a melt temperature of 246° C., a molding pressure of 13.8 MPa, a mold thickness of 0.8 mm, and a mold width of 12.7 mm.
US Pat. No. 10,920,240

METHODS AND COMPOSITIONS FOR THE CONTROL OF RUST FUNGI BY INHIBITING EXPRESSION OF THE HXT1 GENE

BASF AGRICULTURAL SOLUTIO...

8. A method of treatment of plants, comprising applying an effective and non-phytotoxic amount of a dsRNA molecule according to claim 1 to soil where plants grow or are capable of growing, to the leaves and/or the fruit of plants or to the seeds of such plants.
US Pat. No. 10,918,704

MEANS AND METHODS FOR ACTIVE CELLULAR IMMUNOTHERAPY OF CANCER BY USING TUMOR CELLS KILLED BY HIGH HYDROSTATIC PRESSURE AND DENDRITIC CELLS

SOTIO a.s., Prague (CZ)

1. A method for producing a mature loaded dendritic cell comprising:(i) obtaining monocytes from a patient,
(ii) culturing the monocytes in the presence of GM-CSF and IL-4 to obtain immature dendritic cells,
(iii) obtaining tumor cells derived from the patient or from one or more tumor cell lines,
(iv) inducing apoptosis in the tumor cells by applying high hydrostatic pressure (HHP) of 100 MPa to 300 MPa for 10 min to 2 h,
(v) loading in vitro the immature dendritic cells obtained in step (ii) with the apoptotic tumor cells obtained in step (iv) to obtain loaded dendritic cells, wherein the immature dendritic cells are combined with the apoptotic tumor cells at a ratio between about 1:1 to about 10:1, and
(vi) further maturing in vitro the loaded dendritic cells obtained in step (v) by treating the loaded dendritic cells with Poly I:C or LPC to obtain loaded matured dendritic cells.
US Pat. No. 10,919,985

NANOCELLULOSE COMPOSITIONS AND PROCESSES TO PRODUCE SAME

GranBio Intellectual Prop...

1. A composition comprising hydrophobic nanocellulose, wherein said nanocellulose contains about 0.5 wt % sulfur content or less, and wherein said nanocellulose is characterized by a crystallinity of at least 60%.
US Pat. No. 10,920,241

BIOLOGICAL CONTROL OF PLANT VIRUSES

LOOIJE APPLICATIONS B.V.,...

1. A Pepino mosaic virus comprising a nucleic acid molecule with a nucleic acid sequence that encodes phenylalanine at the position corresponding to 1052 of SEQ ID NO:2.
US Pat. No. 10,918,705

COSTIMULATION OF CHIMERIC ANTIGEN RECEPTORS BY MYD88 AND CD40 POLYPEPTIDES

Bellicum Pharmaceutics, I...

1. A modified cell comprising a nucleic acid comprising a first polynucleotide encoding a chimeric stimulating molecule, wherein the chimeric stimulating molecule comprises:(i) a MyD88 polypeptide or a truncated MyD88 polypeptide lacking the TIR domain;
(ii) a CD40 cytoplasmic polypeptide region lacking the CD40 extracellular domain; and
(iii) a membrane targeting region;
wherein the chimeric stimulating molecule does not include a multimeric ligand binding region, and
wherein the chimeric stimulating molecule is constitutively active.
US Pat. No. 10,919,986

POROUS POLYMERIC CELLULOSE PREPARED VIA CELLULOSE CROSSLINKING

Nanopareil, LLC, Dakota ...

1. A hybrid cellulose membrane composition comprising:a first electrospun nanofiber, wherein the first electrospun nanofiber comprises cellulose; and
a second electrospun nanofiber, wherein the second electrospun nanofiber comprises a non-cellulose based polymer; wherein the composition comprises pores and/or channels; wherein the cellulose is crosslinked by a crosslinking agent; wherein the crosslinking agent is an aldehyde, an organochloride, an ether, a multi-functional carboxylic acid, glycerol, a urea derivative, a glycidyl ether, or a mixture thereof; and wherein the composition comprises at least 30 wt. % of the cellulose.
US Pat. No. 10,920,242

NON-MEIOTIC ALLELE INTROGRESSION

Recombinetics, Inc., Eag...

1. A method of genetically modifying an isolated bovine cell in which a horned gene sequence of the isolated bovine cell is edited to a polled gene sequence, the method comprising:introducing to the isolated bovine cell a transcription activator-like effector nuclease (TALEN) that specifically binds and cleaves a target DNA sequence in the horned gene sequence of said bovine cell; and
introducing into the isolated bovine cell an HDR template that comprises at least a portion of the polled gene sequence flanked by sequences homologous to the target DNA site,
wherein the horned gene sequence is converted into a polled gene sequence.
US Pat. No. 10,918,706

SUBUNIT VACCINE DELIVERY PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES

Cornell University, Itha...

1. A method of eliciting an immune response in a mammal, said method comprising:providing a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides and
administering the probiotic cell to the mammal under conditions effective to elicit the immune response.
US Pat. No. 10,920,244

COMPOSITIONS FOR TARGETING CONDUCTING AIRWAY CELLS COMPRISING ADENO-ASSOCIATED VIRUS CONSTRUCTS

The Trustees of the Unive...

1. An adeno-associated virus (AAV) vector useful for targeting conducting airway cells, wherein the vector has an AAV capsid and an expression cassette packaged therein, wherein the capsid comprises a chimeric capsid protein comprising an airway conducting cell targeting peptide and at least amino acids (aa) 1 to aa 389 and aa 524 to aa 736 of an AAV9 capsid protein having the amino acid sequence of SEQ ID NO: 2, wherein the airway conducting cell targeting peptide comprises one of (a) to (d):(a) aa 447 to aa 521 of the amino acid sequence of SEQ ID NO:1;
(b) aa 450 to aa 469 of the amino acid sequence of SEQ ID NO:1 and aa 487 to aa 505 of the amino acid sequence of SEQ ID NO:1;
(c) aa 487 to aa 505 of the amino acid sequence of SEQ ID NO:1; or
(d) aa 447 to aa 469 of the amino acid sequence of SEQ ID NO:1;
wherein the airway conducting cell targeting peptide is located in the chimeric capsid protein in a location corresponding to the location of the targeting peptide in the AAV6 capsid protein, wherein the corresponding location of the airway conducting cell targeting peptide location is determined by a sequence alignment between the chimeric capsid protein and the AAV9 capsid protein, and wherein the expression cassette comprises at least one AAV inverted terminal repeat sequence and a heterologous gene operably linked to regulatory sequences which permit expression of the heterologous gene in the conducting airway cells.
US Pat. No. 10,918,708

STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDES AND CONJUGATES THEREOF

Pfizer Inc., New York, N...

1. An activated Streptococcus pneumoniae serotype 10A capsular polysaccharide, wherein said polysaccharide has a molecular weight between 50 and 400 kDa, 50 and 350 kDa, 50 and 300 kDa, 50 and 250 kDa, 50 and 200 kDa, 100 and 300 kDa, 100 and 250 kDa, or 100 and 200 kDa.
US Pat. No. 10,920,245

GENE THERAPY FOR AMYOTROPHIC LATERAL SCLEROSIS AND OTHER SPINAL CORD DISORDERS

GENZYME CORPORATION, Cam...

1. A recombinant gene delivery vector, comprising a recombinant AAV vector encoding a DNA binding domain of hypoxia-inducible factor 1-alpha (HIF 1-alpha) fused to a herpes simplex virus virion protein 16 (HSV VP 16) transcriptional activation domain, wherein the recombinant AAV vector comprises inverted terminal repeats of AAV-2 and an AAV-7 capsid or inverted terminal repeats of AAV-2 and an AAV-8 capsid, wherein the recombinant AAV vector is for treating patients with a motor neuron disorder, wherein the DNA binding domain of HIF 1-alpha fused to the HSV VP 16 transcriptional activation domain is encoded by the nucleotide sequence as shown in SEQ ID NO:1.
US Pat. No. 10,920,246

TARGETED LIPID PARTICLES FOR SYSTEMIC DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES

RAMOT AT TEL-AVIV UNIVERS...

1. A particle for targeted delivery of a nucleic acid to a leukocyte cell, the particle comprising: a lipid membrane suitable for encapsulating a nucleic acid, wherein the lipid membrane comprises Dlin-MC3-DMA, cholesterol, DSPC, DMG-PEG, and DSPE-PEG-maleimide conjugated to a targeting moiety and wherein the targeting moiety is an antibody selected from the group consisting of an anti-CD38 antibody, an anti-CD4 antibody, an anti-CD8 antibody, and an anti-CD3 antibody, or an antigen binding fragment thereof.
US Pat. No. 10,918,710

TEMPERATURE-SENSITIVE ATTENUATED FMDV STRAINS, CONSTRUCTION METHOD AND APPLICATION THEREOF

HARBIN VETERINARY RESEARC...

1. A construction method of a temperature-sensitive attenuated FMDV strain, comprising: constructing a FMDV full-length cDNA infectious cloning plasmid, performing a site-directed mutagenesis to an IRES region of the FMDV full-length cDNA infectious cloning plasmid, obtaining a FMDV genomic RNA by in vitro transcription, and transfecting the FMDV genomic RNA into cells and culturing the cells containing the FMDV genomic RNA at temperatures to rescue the temperature-sensitive attenuated FMDV strain; wherein a cytosine at 351-site on K region loop of IRES domain 4 of the FMDV genomic RNA obtained by the in vitro transcription is mutated to a guanine or an adenine during the site-directed mutagenesis, a base sequence of the K region loop after mutation is 351GUUUAA356 or 351AUUUAA356.
US Pat. No. 10,919,991

HIGH PERFORMANCES MULTIMODAL ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE

Thai Polyethylene Co., Lt...

1. A multimodal polyethylene composition comprising;(A) 30 to 65 parts by weight of a low molecular weight polyethylene having a weight average molecular weight (Mw) of 20,000 to 90,000 g/mol or medium molecular weight polyethylene having a weight average molecular weight (Mw) of more than 90,000 to 150,000 g/mol;
(B) 5 to 40 parts by weight of a first high molecular weight polyethylene having a weight average molecular weight (Mw) of more than 150,000 to 1,000,000 g/mol or a first ultra high molecular weight polyethylene having a weight average molecular weight (Mw) of more than 1,000,000 to 5,000,000 g/mol; and
(C) 10 to 60 parts by weight of a second high molecular weight polyethylene having a weight average molecular weight (Mw) of more than 150,000 to 1,000,000 g/mol or a second ultra high molecular weight polyethylene having a weight average molecular weight (Mw) of more than 1,000,000 to 5,000,000 g/mol
wherein a MI21 of the multimodal polyethylene composition is 3.0 or less, and
a Charpy impact strength at 23° C. of a compressed specimen of the multimodal polyethylene composition is at least 70 kJ/m2, measured by ISO179;
wherein (A), (B), and (C) each have a different weight average molecular weight.
US Pat. No. 10,920,247

METHODS AND SYSTEMS FOR PROPAGATION OF A MICROORGANISM USING A PULP MILL AND/OR A PAPER MILL WASTE BY-PRODUCT, AND RELATED METHODS AND SYSTEMS

POET Research, Inc., Sio...

1. A method of propagating a microorganism, the method comprising:a) combining at least one pulp or paper mill waste by-product and an ionic stabilizing component, wherein the at least one pulp or paper mill waste by-product is chosen from a pulp sludge, a paper sludge, and combinations thereof, wherein the ionic stabilizing component is chosen from one or more salts, at least one stillage composition, corn steep liquor, at least one pulp or paper mill waste by-product liquor, and combinations thereof, and wherein the at least one stillage composition is derived from a grain starch ethanol process,
b) enzymatically hydrolyzing one or more polysaccharides and/or one or more oligosaccharides present in at least one pulp or paper mill waste by-product in the presence of one or more enzymes and into one or more monosaccharides, wherein the one or more enzymes are chosen from one or more cellulase enzymes, one or more hemicellulose enzymes, and combinations thereof;
c) providing a first cell mass of a microorganism that can convert one or more monosaccharides into a biochemical via fermentation; and
d) propagating the first cell mass of the microorganism in a propagation composition that comprises one or more monosaccharides from the enzymatic hydrolysis as a carbon source to propagate the first cell mass of the microorganism into a second cell mass of the microorganism.
US Pat. No. 10,918,711

COMPOSITION COMPRISING ANTIGENS AND A MUCOSAL ADJUVANT AND A METHOD FOR USING

Phibro Animal Health Corp...

1. A method, comprising:administering a first composition mucosally to a mammal, the first composition being an aqueous solution comprising inactivated antigens obtained from a bacteria or virus, and a single adjuvant such that a concentration of adjuvant in the first composition is from 5% to 70% w/w, wherein the single adjuvant is a polyacrylic acid-based mucoadhesive adjuvant; and
parenterally administering to the mammal, a second composition comprising inactivated antigens obtained from the bacteria or virus.
US Pat. No. 10,920,248

METHOD FOR MASS-PRODUCING VINIFERIN USING STEVIOSIDE FROM CELL CULTURE OF GRAPEVINE TISSUE

KOREA RESEARCH INSTITUTE ...

1. A method of mass production of viniferin derived from a grape tree, the method comprising the steps of:(a) transplanting a grape tree tissue fragment on a callus induction medium to induce a grape tree callus;
(b) culturing the induced grape tree callus in a growth medium to grow; and
(c) adding an activity-inducing agent and a solubilizing agent to the grown callus, followed by shaking culture,
wherein the activity-inducing agent and the solubilizing agent in step (c) are methyl jasmonate and stevioside, respectively;
the methyl jasmonate and stevioside are added at a concentration of 50 ?M to 350 ?M and 40 mM to 60 mM, respectively; and
the viniferin is delta (?)-viniferin or epsilon (?)-viniferin.
US Pat. No. 10,918,712

PASSIVE TRANSFER OF IMMUNITY USING RECOMBINANT HERPES SIMPLEX VIRUS 2 (HSV-2) VACCINE VECTORS

ALBERT EINSTEIN COLLEGE O...

1. A method of eliciting an immune response in a first subject against an HSV-2 or HSV-1 infection, comprising passive transfer to the first subject of an amount of a product from a second subject immunized with HSV-2 having a deletion of an entire HSV-2 glycoprotein D-encoding gene in a genome of the HSV-2 and wherein the HSV-2 is phenotypically complemented with a herpes simplex virus-1 (HSV-1) glycoprotein D by propagating the HSV-2 in a complementing cell expressing the HSV-1 glycoprotein D, wherein the product comprises the HSV-2 or antibodies or immune factors induced thereby, effective to elicit an immune response against an HSV-2 or HSV-1 infection.
US Pat. No. 10,918,713

EPITOPES FROM ALLERGEN PROTEINS AND METHODS AND USES FOR IMMUNE RESPONSE MODULATION

La Jolla Institute For Al...

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient, an adjuvant, and an effective amount of a peptide, wherein the peptide consists of the amino acid sequence set forth in SEQ ID NO: 668.
US Pat. No. 10,920,250

MAGNESIUM LACTATE FERMENTATION PROCESS

PURAC BIOCHEM BV, Gorinc...

1. Fermentation process for producing magnesium lactate from a carbon source comprisingproviding a fermentation medium comprising a fermentable carbon source in a fermentation reactor,
fermenting the fermentation medium by means of a lactic acid producing microorganism in the presence of an alkaline magnesium salt to provide a fermentation broth in the fermentation reactor comprising magnesium lactate, and
recovering solid magnesium lactate from the fermentation broth,
wherein during at least 40% of a total operating time of the fermentation process, the recovering of solid magnesium lactate from the fermentation broth is such that an amount of solid magnesium lactate in the fermentation broth in the fermentation reactor is maintained in a range of 10 to 40 vol. %, calculated as solid magnesium lactate in a total of the fermentation broth in the fermentation reactor.
US Pat. No. 10,920,251

MICROBIAL PRODUCTION OF FATS

WILLIAM MARSH RICE UNIVER...

1. A method of producing products in bacteria, comprising:a) aerobically culturing a bacteria in a growth medium until sufficient cell mass is reached;
b) smoothly transitioning from aerobic culturing to culturing under oxygen lean conditions (>0.1% dissolved oxygen (“DO”) to <5% DO) over a course of time of 1-12 hrs;
c) further culturing said bacteria under oxygen lean conditions by only sparging a head space with O2 containing gas until product is formed; and
d) isolating said product from said bacteria, said growth medium, or both.